

iSERA LIFESCIENCES LIMITED

(Formerly known as Covidh Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001 Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

Date: April 21, 2026

To,
The Manager,
Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Subject: Intimation regarding Postal Ballot Notice of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited).

Dear Sir/Madam,

Pursuant to the resolution passed by the Board of Directors of the Company at its meeting held on Tuesday, April 21, 2026, the Company encloses herewith the Postal Ballot Notice dated April 21, 2026, seeking the approval of the Members of the Company by way of Postal Ballot / Remote E-Voting on the following matters:

- a) Increase in Authorised Share Capital of the Company and Consequential Alteration in Capital Clause of the Memorandum of Association;
- b) Adoption of New Set of Memorandum of Association of the Company in Substitution of the Existing Memorandum of Association;
- c) Adoption of New Set of Articles of Association of the Company in Substitution of the Existing Articles of Association;
- d) Enhancement of Limits for Making Investments, Giving Loans or Guarantees and Providing Securities under Section 186 of the Companies Act, 2013;
- e) Approval of Related Party Transaction — Acquisition of up to 100% Equity Shareholding of iSERA Biological Limited through Share Swap;
- f) Acquisition of up to 100% Equity Shareholding of iSERA Biological Limited through Share Swap; and
- g) Issuance of Equity Shares by way of Preferential Issue on Private Placement Basis for Consideration other than Cash (Share Swap).

The remote e-voting will be available during the following period:

Particulars	Date and Time
Commencement of remote e-voting	Wednesday, April 22, 2026 (9:00 A.M. IST)
End of remote e-voting	Thursday, May 21, 2026 (5:00 P.M. IST)

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,

For iSERA Lifesciences Limited
(Formerly known as Covidh Technologies Limited)

(DEEPAKSHI)
Company Secretary & Compliance Officer
Membership No.: A76335

iSERA LIFESCIENCES LIMITED

(Formerly known as Covidh Technologies Limited)

CIN: L72200PN1993PLC252720

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune-411001
Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

NOTICE OF POSTAL BALLOT

(Pursuant to Section 110 of the Companies Act, 2013 read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014)

Dear Member(s),

Notice is hereby given, pursuant to the provisions of Section 108, 110 and other applicable provisions, if any, of the Companies Act, 2013 (the “**Act**”) read with Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014 (“**the Rules**”), and other applicable provisions of the Act and the Rules as amended from time to time, General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 5, 2020, General Circular No. 22/2020 dated June 15, 2020, General Circular No. 33/2020 dated September 28, 2020, General Circular No. 39/2020 dated December 31, 2020, General Circular No. 10/2021 dated June 23, 2021, General Circular No. 20/2021 dated December 8, 2021, General Circular No. 3/2022 dated May 5, 2022, General Circular No. 11/2022 dated December 28, 2022, General Circular No. 09/2023 dated September 25, 2023, General Circular No. 09/2024 dated September 19, 2024 and General Circular No. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs (“**MCA Circulars**”), Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”), Secretarial Standard on General Meetings (“**SS-2**”) issued by the Institute of Company Secretaries of India and other applicable laws, rules and regulations (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), to transact the items of special businesses as set out in this Postal Ballot Notice proposed to be passed by the Members of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) (“**the Company**”) through remote e-voting only, i.e., voting through electronic means.

The Board of Directors (the “**Board**”) has appointed **CS Anuj Gupta**, Practicing Company Secretary (Membership No.: 31025; COP No.: 13025), Proprietor of **M/s Anuj Gupta & Associates, Company Secretaries**, as the Scrutinizer to conduct the Postal Ballot through remote e-voting process in a fair and transparent manner.

In compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and pursuant to the provisions of Section 108 and 110 of the Act read with the Rules, the MCA Circulars and SS-2, the Company is providing remote e-voting facility to its Members, to enable them to cast their votes electronically instead of submitting the Postal Ballot Form physically. The Company has entered into an agreement with **MUFG Intime India Private Limited** for facilitating voting through electronic means, as the authorized agency. The instructions for remote e-voting are appended to this Notice. This Notice is also available on the website of the Company at **www.covidhtechnologies.com** and on the website of BSE Limited at **www.bseindia.com**.

In accordance with the provisions of the MCA Circulars, the Company has made arrangements for the shareholders to register their e-mail addresses. Therefore, those shareholders who have not yet registered their e-mail addresses are requested to register the same by following the procedure set out in the notes to this Postal Ballot Notice. The manner of voting remotely by members holding shares in dematerialised mode and physical mode is set out in the notes to this Postal Ballot Notice.

In compliance with the requirements of the MCA Circulars, the Company will send the Postal Ballot Notice by email only to those members who have registered their email addresses with the Company or with the

depository / depository participants, and the communication of assent or dissent of the members will take place only through the remote e-voting system. Hence, hard copies of the Postal Ballot Notice, postal ballot forms, and pre-paid business reply envelopes are not being sent to the members. Further, the Company has made necessary arrangements for members to register their email addresses. Therefore, those members who have not yet registered their email address are requested to do so by following the procedure set out in the Notes to this Postal Ballot Notice.

Members are requested to carefully read the instructions in this Postal Ballot Notice and record their assent (FOR) or dissent (AGAINST) only through the remote e-voting process not later than **5:00 P.M. (IST) on Thursday, 21 May, 2026** (being the last date of remote e-voting). Remote e-voting will be blocked by MUFG Intime India Private Limited immediately thereafter and will not be allowed beyond the said date and time.

After completion of scrutiny of the votes, the Scrutinizer will submit his report to the Company. The results of the voting conducted through Postal Ballot (through the remote e-voting process), along with the Scrutinizer's Report, will be announced by the Company on or before **Saturday, 23 May, 2026** at any time before 5:00 P.M. (IST). The said results will be displayed on the website of the Company at **www.covidhtechnologies.com** and on the website of MUFG Intime India Private Limited at **https://instavote.linkintime.co.in**, and will also be communicated to BSE Limited ("BSE"), where the Company's equity shares are listed, and made available on their respective websites.

The Board of Directors of the Company proposes to obtain the consent of the Members by way of Postal Ballot for the matters stated herein, as set out in the Resolutions appended below.

The Explanatory Statement pursuant to Section 102, 110 and other applicable provisions, if any, of the Act, pertaining to the said resolutions and setting out the material facts and reasons for the Resolutions, is also annexed herewith. You are requested to peruse the proposed Resolutions along with the Explanatory Statement and thereafter record your assent or dissent by means of the remote e-voting facility provided by the Company.

RESOLUTIONS TO TRANSACT THE SPECIAL BUSINESS:

Item No. 1 - INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY AND CONSEQUENTIAL ALTERATION IN CAPITAL CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT THAT pursuant to the provisions of Section 13, 61(1)(a), 64 and all other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification (s) or re-enactment thereof, for the time being in force) and the relevant rules framed there under, any other applicable law(s), regulation(s), rule(s) or guideline(s) if any, and in accordance with the applicable provisions of the Articles of Association of the Company, the consent of members of the company be and is hereby accorded to increase the Authorized Share Capital of the Company from the existing Rs. 11,00,00,000/- (Rupees Eleven Crore Only) divided into 1,10,00,000 (One Crore Ten Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 25,00,00,000/- (Rupees Twenty-Five Crore Only) divided into 2,50,00,000 (Two Crore Fifty Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each, ranking pari-passu in all respects with the existing Equity Shares of the Company.

RESOLVED FURTHER THAT the Capital existing Clause (Clause V) of the Memorandum of Association of the Company is substituted with the following new Clause V:

"V. The Authorised Share Capital of the Company is Rs. 25,00,00,000/- (Rupees Twenty-Five Crore Only) divided into 2,50,00,000 (Two Crore Fifty Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each."

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, any of the Directors or Key Managerial Personnel of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things as may be deemed necessary, desirable or expedient, including filing, signing, verifying and executing all such forms (including e-forms), applications, papers and documents as may be required with the Registrar of Companies, Pune or any other authority, and to do all such acts, deeds, matters and things as may be necessary and incidental for giving effect to the aforementioned resolution."

Item No. 2 – ADOPTION OF NEW SET OF MEMORANDUM OF ASSOCIATION OF THE COMPANY AS PER THE PROVISIONS OF THE COMPANIES ACT, 2013, IN SUBSTITUTION OF THE EXISTING MEMORANDUM OF ASSOCIATION

To consider and if thought fit, to pass the following resolution with or without modification(s) as a **Special Resolution:**

"RESOLVED THAT THAT pursuant to the provisions of Sections 4, 13 and 15 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act"), read with the Companies (Incorporation) Rules, 2014 and other applicable rules made thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and in accordance with the any other applicable law(s), regulation(s), rule(s) or guideline(s) if any, and subject to such approvals, consents and permissions as may be required from the Registrar of Companies ("ROC"), or any other regulatory or statutory authority(ies), the consent of the Members of the Company be and is hereby accorded to substitute the existing Memorandum of Association of the Company with a new set of Memorandum of Association in substitution of and to the entire exclusion of the existing Memorandum of Association, in order to align with the applicable provisions of the Companies Act, 2013(with the format prescribed in Table A of Schedule I to the Companies Act, 2013) and the rules made thereunder.

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, any of the Directors or Key Managerial Personnel of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things as may be deemed necessary, desirable or expedient, including filing, signing, verifying and executing all such forms (including e-forms), applications, papers and documents as may be required with the Registrar of Companies, Pune or any other authority, and to do all such acts, deeds, matters and things as may be necessary and incidental for giving effect to the aforementioned resolution"

Item No. 3 – ADOPTION OF NEW SET OF ARTICLES OF ASSOCIATION OF THE COMPANY AS PER THE PROVISIONS OF THE COMPANIES ACT, 2013, IN SUBSTITUTION OF THE EXISTING ARTICLES OF ASSOCIATION

To consider and if thought fit, to pass the following resolution with or without modification(s) as a **Special Resolution:**

"RESOLVED THAT in terms of the provisions of Sections 5, 14 and 15 read with other applicable provisions of the Companies Act, 2013 ("the Act") (including any amendment, re-enactment or statutory modification thereof) and the Rules made thereunder, as amended from time to time and any other applicable law(s), regulation(s), rule(s) or guideline(s) if any, subject to such approvals, consents and permissions as may be required from the Registrar of Companies ("ROC"), or any other regulatory or statutory authority(ies), as may be applicable, the consent of the Members of the Company be and is hereby accorded to substitute the existing Articles of Association of the Company with a new set of Articles of Association in substitution of and to the entire exclusion of the existing Articles of Association, in order to align with the applicable provisions of the Companies Act, 2013 (as per the format mentioned in the Table

F of Schedule I to the Act)and the rules made thereunder.

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, any of the Directors or Key Managerial Personnel of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things as may be deemed necessary, desirable or expedient, including filing, signing, verifying and executing all such forms (including e-forms), applications, papers and documents as may be required with the Registrar of Companies, Pune or any other authority, and to do all such acts, deeds, matters and things as may be necessary and incidental for giving effect to the aforementioned resolution"

Item No. 4 – ENHANCEMENT OF LIMITS FOR MAKING INVESTMENTS, GIVING LOANS OR GUARANTEES AND PROVIDING SECURITIES UNDER SECTION 186 OF THE COMPANIES ACT, 2013

To consider and if thought fit, to pass the following resolution with or without modification(s) as a **Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 186 read with Section 179(3)(f) and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Meetings of Board and its Powers) Rules, 2014, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and subject to such approvals, consents and permissions as may be required from the Registrar of Companies ("ROC"), or any other regulatory or statutory authority(ies), as may be applicable the consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the "Board", which term shall be deemed to include any Committee thereof or any person(s) authorised by the Board in this behalf) to:

- a. Give any loan to any person(s) or other body corporate(s);
- b. Give any guarantee or provide security in connection with a loan to any person(s) or other body corporate(s); and
- c. Acquire by way of subscription, purchase or otherwise, the securities of any other body corporate,

from time to time, in one or more tranches, as the Board may in its absolute discretion deem beneficial and in the interest of the Company, for an aggregate amount not exceeding Rs. 1,000,00,00,000/- (Rupees One Thousand Crore Only) outstanding at any point of time, notwithstanding that such investments, outstanding loans given or to be given and guarantees and security provided are in excess of the limits prescribed under Section 186 of the Companies Act, 2013.

RESOLVED FURTHER THAT the Board hereby confirms that there is no subsisting default in repayment of any deposit or interest thereon, and that prior approval of the Public Financial Institutions, wherever required, shall be obtained before giving any loan or guarantee or providing any security or making any acquisition that would result in exceeding the limits prescribed under Section 186(2) of the Companies Act, 2013.

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, any of the Directors or Key Managerial Personnel of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things as may be deemed necessary, desirable or expedient, including filing, signing, verifying and executing all such forms (including e-forms), applications, papers and documents as may be required with the Registrar of Companies, Pune or any other authority, and to do all such acts, deeds, matters and things as may be necessary and incidental for giving effect to the aforementioned resolution."

Item No. 5 - APPROVAL OF RELATED PARTY TRANSACTION – ACQUISITION OF UP TO 100% EQUITY SHAREHOLDING OF iSERA BIOLOGICAL LIMITED (TARGET COMPANY) THROUGH SHARE SWAP

To consider and if thought fit, to pass the following resolution with or without modification(s) as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the applicable provisions of the Companies Act, 2013, including Section

188 read with Section 177 and other applicable provisions, if any, of the Companies Act, 2013 and the Rules made thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and in accordance with the Company's Policy on Materiality of Related Party Transactions, and subject to such other approvals, consents and permissions as may be necessary, the consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the "Board", which term shall be deemed to include any Committee thereof or any person(s) authorised by the Board in this regard) to enter into and execute the Related Party Transaction, being the acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited (CIN: U85300PN2016PLC165483) ("**iSERA Biological**"), from the existing shareholders of iSERA Biological Limited, who are related parties of the Company under Section 2(76) of the Companies Act, 2013, for a total consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), to be discharged entirely by way of issuance and allotment of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share of face value Rs. 10/- each (including a premium of Rs. 38.20/- per share), on a preferential basis for consideration other than cash (Share Swap), at a Swap Ratio of 1:1 (one equity share of iSERA Lifesciences Limited for every one equity share of iSERA Biological Limited), as certified by Mr. Bhavesh M Rathod, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708) in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) and Mr. Karan Chetan Shah, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561) in respect of iSERA Biological Limited, vide their respective Valuation Reports dated April 21, 2026. Upon completion of the said acquisition, iSERA Biological Limited shall become a Wholly Owned Subsidiary of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited).

RESOLVED FURTHER THAT no related party shall be entitled to vote on this resolution, in accordance with the Company's Policy on Materiality of Related Party Transactions.

RESOLVED FURTHER THAT the Board be and is hereby severally authorised to finalise, execute and deliver the Share Swap Agreement and all such other agreements, documents, instruments and writings as may be deemed necessary, with power to alter and vary the terms and conditions of such contracts / arrangements / transactions, settle all questions, difficulties or doubts that may arise in this regard, and to do all such acts, deeds, matters and things as may be necessary, desirable or expedient to give effect to the foregoing resolution, including filing of all necessary e-forms and documents with the Registrar of Companies, Pune or any other authority."

Item No. 6 – ACQUISITION OF UP TO 100% EQUITY SHAREHOLDING OF iSERA BIOLOGICAL LIMITED THROUGH SHARE SWAP

To consider and if thought fit, to pass the following resolution with or without modification(s) as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 186 read with Section 179(3)(j) and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the rules made thereunder, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and in accordance with the provisions of the Memorandum of Association and Articles of Association of the Company, and subject to such other approvals, sanctions, consents and permissions as may be required from any statutory, regulatory or governmental authority, including the receipt of In-Principle Approval from BSE Limited, the consent of the Members of the Company be and is hereby accorded for the acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares, representing up to 100% of the paid-up equity share capital of iSERA Biological Limited (CIN: U85300PN2016PLC165483), an unlisted public company, for a total consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), at a price of Rs. 48.20/- (Rupees

Forty-Eight and Paise Twenty Only) per equity share, as determined by the Valuation Report dated April 21, 2026, issued by Mr. Karan Chetan Shah, an independent Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561) (the "**Purchase Consideration**").

RESOLVED FURTHER THAT in consideration of the above acquisition, the consent of the Members of the Company be and is hereby accorded for the issuance and allotment of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of the Company having face value of Rs. 10/- (Rupees Ten Only) each, at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share (including a premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty Only) per share), to the existing shareholders of iSERA Biological Limited by way of Share Swap, thereby discharging the entire Purchase Consideration for the acquisition of iSERA Biological Limited, in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("**SEBI ICDR Regulations**"), including any amendments, statutory modification(s) or re-enactment(s) thereof for the time being in force.

RESOLVED FURTHER THAT upon the allotment of the said equity shares, iSERA Biological Limited shall become a Wholly Owned Subsidiary of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) (the "Company").

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the "Board", which term shall be deemed to include any Committee thereof or any person(s) authorised by the Board in this behalf) be and is hereby authorised to take all necessary steps to give effect to this resolution, including but not limited to finalising and executing the Share Swap Agreement and all ancillary documents, filing of necessary forms and documents with the Registrar of Companies, Pune, making necessary disclosures to BSE Limited and such other stock exchanges and regulatory authorities as may be required, and obtaining any approvals as may be necessary.

RESOLVED FURTHER THAT any Director or the Company Secretary of the Company be and is hereby severally authorised to decide and finalise the terms and conditions of the acquisition, sign and submit all necessary applications, e-forms and documents with the Registrar of Companies, Pune or any other appropriate authority, and to perform all such acts, deeds, matters and things as may be necessary, desirable or expedient for and on behalf of the Company for the purpose of giving effect to the aforesaid resolution."

Item No. 7 – ISSUANCE OF EQUITY SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS FOR CONSIDERATION OTHER THAN CASH (SHARE SWAP)

To consider and if thought fit, to pass the following resolution with or without modification(s) as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 23, 42, 62(1)(c) and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with the Companies (Share Capital and Debentures) Rules, 2014 and the Companies (Prospectus and Allotment of Securities) Rules, 2014, Chapter V and other applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the 'SEBI ICDR Regulations'), the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (the 'PIT Regulations'), applicable provisions of the Foreign Exchange Management Act, 1999, as amended or restated ("FEMA"), the Foreign Exchange Management (Non-debt Instruments) Rules, 2019, as amended, and rules, circulars, notifications, regulations and guidelines issued under FEMA, and subject to any other rules, regulations, guidelines, notifications, circulars and clarifications issued from time to time by the Ministry of Corporate Affairs ('MCA'), the Reserve Bank of India ('RBI'), BSE Limited ('BSE') where the shares of the Company are listed (hereinafter referred to as the 'Stock Exchange') and/or any other statutory / government / regulatory authority, and rules and regulations framed thereunder as amended

(including any statutory modification(s) thereto or re-enactment(s) thereof for the time being in force), and pursuant to the provisions of the Memorandum of Association and Articles of Association of the Company, and subject to the approval(s), consent(s), permission(s) and sanction(s), if any, of the appropriate authorities as may be required, and subject to such conditions and modifications as may be prescribed by any of the applicable authorities while granting any such approval(s), consent(s), permission(s) and sanction(s), and which are agreed to by the Board of Directors of the Company, the consent of the Members of the Company be and is hereby accorded to create, offer, issue and allot up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares (hereinafter referred to as "Equity Shares") of the Company having face value of Rs. 10/- (Rupees Ten Only) each, at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share (including a premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty Only) per share), as determined in accordance with Regulation 164(2) of Chapter V of the SEBI ICDR Regulations and the Valuation Reports dated April 20, 2026, issued by Mr. Bhavesh M Rathod, an independent Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708) in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), and Mr. Karan Chetan Shah, an independent Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561) in respect of iSERA Biological Limited, aggregating to Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only) ("**Purchase Consideration**"), on a preferential allotment basis, for consideration other than cash (Share Swap), to the 196 (One Hundred and Ninety-Six) proposed allottees, being the existing shareholders (Promoter, Promoter Group and Non-Promoter) of iSERA Biological Limited, whose names, categories and number of equity shares proposed to be allotted are set out in the table below, for consideration other than cash, being the payment to be made towards the acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares representing up to 100% of the paid-up equity share capital ("**Sale Shares**") of iSERA Biological Limited, on such terms and conditions as may be determined by the Board in accordance with the SEBI ICDR Regulations and other applicable laws:

Sr. No.	Name of Proposed Allottee / Investor (Shareholder of iSERA Biological Limited)	Category (Promoter / Non-Promoter)	No. of Equity Shares to be Allotted
Promoter & Promoter Group Allottees:			
1	SHUBHANGI DHANRAJ GARAD	Promoter	27,55,000
2	SUMEET DHANRAJ GARAD	Promoter	11,92,000
3	PRATAP DADASAHEB DESHMUKH	Promoter	7,85,500
4	RITU DHANRAJ GARAD	Promoter	7,46,000
5	ARCHANA KAKASAHEB LONKAR	Promoter	4,95,000
6	NANDKUMAR SUBHASH KADAM	Promoter	4,56,500
7	DHAIRYASHEEL VASANTRAO YADAV	Promoter	4,50,500
8	VENKATESH MADHAV BHAT	Promoter Group	1,50,000
9	PRAVIN VAMAN SURYARAO	Promoter Group	1,00,000
10	MADAN MANOHAR BALLAL	Promoter Group	1,00,000
11	DARSHANA VIKAS CHAVAN	Promoter Group	1,00,000
12	AADHAR KUMAR	Promoter Group	1,00,000
13	ISHITA RAJESH KUMAR	Promoter Group	1,00,000

14	UJJWALA ANIL MANE	Promoter Group	1,00,000
15	JYOTI MANESH WAGHIRKAR	Promoter Group	1,00,000
16	ARCHANA SITARAM KALE	Promoter Group	1,00,000
17	BABASAHEB MAHADEO BHOSALE	Promoter Group	80,000
18	SANJAY RAMCHANDRA TARLEKAR	Promoter Group	75,000
19	ANITA SUNIL NAIR	Promoter Group	75,000
20	KAMLAKAR NIVRUTTI DANDWATE	Promoter Group	70,000
21	SANJIV DATTATRAY JADHAV	Promoter Group	50,000
22	SHITAL TUSHAR PAWAR	Promoter Group	50,000
23	SANTOSH MADHAVRAV NAIK	Promoter Group	50,000
24	YOGESH INDRAJIT SOMWANSHI	Promoter Group	50,000
25	LATA SANJIV JADHAV	Promoter Group	50,000
26	SUNITA SANTOSH PATIL	Promoter Group	30,000
27	SUMAN RAVINDRA KUNJIR	Promoter Group	30,000
28	SADHANA DIGAMBAR JOSHI	Promoter Group	25,000
29	DILIP GANESH KULKARNI	Promoter Group	25,000
30	ANANT KAMLAKAR DANDAWATE	Promoter Group	25,000
31	REKHA ANIL PATIL	Promoter Group	20,000
32	DR PATIL SACHIN SHRIDHAR	Promoter Group	10,000
33	MILIND YOGESHWAR BAM	Promoter Group	10,000
34	NITIN RAMESH KULKARNI	Promoter Group	10,000
35	NIRANJAN VINAYAK DESHPANDE	Promoter Group	10,000
36	AMBADAS DATTATRAYA SHINDE	Promoter Group	10,000
37	JITENDRA PRABHAKAR NENE	Promoter Group	10,000
38	ABHIJIT MAHADEV VEER	Promoter Group	10,000
39	PRASAD DILIP NAGARE	Promoter Group	7,500
	Non-Promoter Allottees:		
40	VINEET ARORA	Non - Promoter	1,41,600
41	KUNAL DEEPAK AGASHE	Non - Promoter	1,07,600
42	NEVILLE MANECKJI	Non - Promoter	99,400
43	DEVANATHAN GOVINDARAJAN	Non - Promoter	91,600
44	RAVI NATHAN IYER	Non - Promoter	91,600
45	DARSHAN GANGOLLI	Non - Promoter	83,200
46	MANGINA S RAO	Non - Promoter	41,600
47	AMOGH GIRISH BRAHME	Non - Promoter	30,400

48	DAMINI SANDEEP GHATE	Non - Promoter	27,200
49	MAYUR PRAKASH KARDILE	Non - Promoter	25,600
50	PARTH YASHODHAN WANAGE	Non - Promoter	25,000
51	UMA SANDEEP GHATE	Non - Promoter	20,800
52	PRATIK SHUBHKARAN SANGHI	Non - Promoter	20,000
53	MANSHA NIKHIL CHAWLA	Non - Promoter	13,000
54	SANJAY EKNATH BHOSALE	Non - Promoter	11,200
55	JYOTI KETAN VAKHARIA	Non - Promoter	1,86,400
56	NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND	Non - Promoter	10,00,000
57	M7 GLOBAL FUND PCC - CELL DEWCAP FUND	Non - Promoter	4,24,800
58	SAURAV RAIDANI	Non - Promoter	3,08,000
59	JAYARAMAN VISHWANATHAN	Non - Promoter	2,16,000
60	RAJESH CHANDRAKANT VAISHNAV	Non - Promoter	2,00,000
61	MORDE FOODS PRIVATE LIMITED	Non - Promoter	2,00,000
62	ERINOME ADVISORS LLP	Non - Promoter	2,00,000
63	GUHAPRIYA SRIDHAR	Non - Promoter	1,90,000
64	RAHUL HEMANTKUMAR MEHTA	Non - Promoter	8,000
65	ASMITA ROHAN PAI	Non - Promoter	1,75,000
66	EUDORA VENTURES LLP	Non - Promoter	1,50,000
67	DOVETAIL GLOBAL FUND PCC ALL SEASONS INDIA OPPORTUNITIES FUND	Non - Promoter	1,50,000
68	DEEPAK AGASHE HUF	Non - Promoter	1,41,600
69	SHANTI KALIAPPAN	Non - Promoter	1,41,600
70	FAT PANDA REALTY LLP	Non - Promoter	1,30,000
71	SHEETAL MEHTA	Non - Promoter	1,16,600
72	RAHUL CHANDRASINGH MEHTA	Non - Promoter	1,06,600
73	MARIETTA BARRETO	Non - Promoter	1,00,000
74	3STATE VENTURES PTE. LTD.	Non - Promoter	1,00,000
75	NIKHIL TYAGI	Non - Promoter	1,00,000
76	AMIT J DHOLAKIA HUF	Non - Promoter	1,00,000
77	VISHAL ULHAS DHUMAL	Non - Promoter	87,000
78	DEEPSHIKHA ARORA	Non - Promoter	83,200
79	SAJID UMEDALI DHROLIA	Non - Promoter	83,200
80	KULBHUSHAN PARASHAR	Non - Promoter	83,200

81	ANURADHA HARSHAL MORDE	Non - Promoter	83,200
82	REX EQUITY	Non - Promoter	83,200
83	KALAWATI KISHOR THAKKAR	Non - Promoter	80,000
84	SUNIL POPATLAL NAHAR	Non - Promoter	66,600
85	RASHMI YASHDEEP JOSHI	Non - Promoter	60,000
86	BHAVNA GOTHI	Non - Promoter	50,000
87	MUKKTA NEVILLE MANECKJI	Non - Promoter	50,000
88	VIKAS ARORA	Non - Promoter	50,000
89	ABHAY PRABHAKAR HAVALDAR	Non - Promoter	50,000
90	MALIK AMIRBHAI CHARANIYA	Non - Promoter	49,600
91	ASHOK BHAWANDAS AWTANI	Non - Promoter	42,600
92	DIVESH WADHAWAN	Non - Promoter	41,600
93	NETRADEEP EYE HOSPITAL PRIVATE LTD	Non - Promoter	41,600
94	AMISHA NIRAJ VORA	Non - Promoter	41,600
95	NERGIS GAURAV PARIKH	Non - Promoter	41,600
96	SAROD REALITY PRIVATE LIMITED	Non - Promoter	41,600
97	PRATIM SENGUPTA	Non - Promoter	41,600
98	BIJAL KUNAL THAKKAR	Non - Promoter	37,600
99	SIDDARTH MURALI KONTHATH	Non - Promoter	33,600
100	JASPRIT J BUMRAH	Non - Promoter	33,600
101	SHILPA ASHWIN RANGDAL	Non - Promoter	33,600
102	VINIT BIPIN SHAH	Non - Promoter	33,600
103	ROHIT SHARMA	Non - Promoter	33,600
104	DILIP KESHRIKAL SANKLECHA	Non - Promoter	25,000
105	CHANDRASHEKHAR RAJARAM KULKARNI	Non - Promoter	20,000
106	AAMIR KHAN	Non - Promoter	17,600
107	KANNAN KRISHNAMURTI NAIDU	Non - Promoter	17,600
108	CHANNA KESHAVA HOSAGAVI	Non - Promoter	16,000
109	RANBIR RISHI KAPOOR	Non - Promoter	16,000
110	SHILPA NARENDRA HIRANI	Non - Promoter	16,000
111	BIMAL PAREKH	Non - Promoter	16,000
112	KINGSMAN WEALTH MANAGEMENT PRIVATE LIMITED	Non - Promoter	16,000
113	SUNIL GOVINDLAL BHANDARI	Non - Promoter	16,000
114	JASKARAN SINGH	Non - Promoter	16,000

115	KISHORE KANJI THAKKAR	Non - Promoter	16,000
116	ARUN MAFATLAL PRAJAPATI	Non - Promoter	16,000
117	BIBHAS DASGUPTA	Non - Promoter	16,000
118	MANOJ BAVANJIBHAI BAVARIA	Non - Promoter	16,000
119	AJAY AGNIHOTRI	Non - Promoter	16,000
120	JYOTSNA MEHTA	Non - Promoter	15,100
121	MANOJ SHIV LAUNGANI	Non - Promoter	15,000
122	SHALINI ASHOK CHAWLA	Non - Promoter	13,000
123	ANKITA CHOPRA	Non - Promoter	12,800
124	AXE FORTUNE CAPITAL ADVISORS LLP	Non - Promoter	12,800
125	ABHISHEK NARBARIA	Non - Promoter	12,800
126	UMESH KUMAR SAHAY	Non - Promoter	12,800
127	RESHMA MANOJ MOHNANI	Non - Promoter	12,800
128	RASHMI SARAFF	Non - Promoter	10,000
129	DINESHKUMAR S RAWLANI	Non - Promoter	9,600
130	SETHIYA SACHIN KANTILAL	Non - Promoter	9,600
131	ESHA SAVLANI	Non - Promoter	9,600
132	S NAGESHWARAN	Non - Promoter	8,000
133	MINDSCOPE ADVISORS LLP	Non - Promoter	8,000
134	MUKESH MANOHAR YEOLE	Non - Promoter	8,000
135	SRINIVASAN ROHINI	Non - Promoter	8,000
136	ILESH H SANGHANI	Non - Promoter	8,000
137	ARWA ALVARES	Non - Promoter	8,000
138	LADDHA NIKHIL RAMESHKUMAR	Non - Promoter	8,000
139	BHAKTI BIMAL PAREKH	Non - Promoter	8,000
140	PRANAV NAVINCHANDRA DOCTOR	Non - Promoter	8,000
141	KALLAM SRINIVAS REDDY	Non - Promoter	8,000
142	NEELA GOPALAKRISHNAN	Non - Promoter	8,000
143	WINNER IMPEX PVT LTD	Non - Promoter	8,000
144	PRAGNESH A SHAH	Non - Promoter	8,000
145	PARUL KARTIK VAKHARIA	Non - Promoter	8,000
146	KRISHNAKUMAR RATANKUMAR MOHTA	Non - Promoter	8,000
147	NIMISHA GORAKSHAKAR	Non - Promoter	8,000
148	SUNIL SURESHCHANDRA PHADE	Non - Promoter	8,000
149	KAPIL DHIRAJ THAKKAR	Non - Promoter	8,000

150	TAPAS SAHA	Non - Promoter	8,000
151	MAULALI CHANDSAHEB JAMADAR	Non - Promoter	8,000
152	AAMER DE	Non - Promoter	8,000
153	DHANANJAY PUNDLIK WAKUDKAR	Non - Promoter	8,000
154	SRIRAM JEYARAMAN HUF	Non - Promoter	8,000
155	VINAY KUMAR	Non - Promoter	8,000
156	GIRISH PUKHRAJ PORWAL	Non - Promoter	8,000
157	MUKESH BHAGWANLAL SHINGI	Non - Promoter	8,000
158	MANISH SHANKARLAL RATHI	Non - Promoter	8,000
159	SAHAJ BIMAL PAREKH	Non - Promoter	8,000
160	SAMPATH KUMAR AMUDHA	Non - Promoter	6,400
161	PONNAKATTI RAJAN UDAY KUMAR	Non - Promoter	6,400
162	PONNAGATIKUPPUSWAMY JAYARAMAN	Non - Promoter	6,400
163	PONNAI CHOKALINGAM MANI	Non - Promoter	6,400
164	JAYANT DIGAMBAR PATKAR	Non - Promoter	6,400
165	NEHA ALTAMASH AHMED	Non - Promoter	6,400
166	PRANAY PRITHVIRAJ CHOUHAN	Non - Promoter	6,400
167	NRIP NIHALANI	Non - Promoter	6,400
168	VERSHA SHARMA	Non - Promoter	6,400
169	ASHISH SURJEET MAKHIJANI	Non - Promoter	6,400
170	MURALI NAGARAJAN	Non - Promoter	6,400
171	KARAN RAJEEV GOYAL	Non - Promoter	6,400
172	ROSHAAN MADHUKAR NARKEDAYY	Non - Promoter	6,400
173	ARCHANA AMAR MULE	Non - Promoter	6,400
174	VINAYAK CHANDRAKANT SANAS	Non - Promoter	6,400
175	RAM PRASAD LADI	Non - Promoter	6,400
176	SHIFA MAKSUD MULANI	Non - Promoter	6,400
177	SIDDARTH JAIN	Non - Promoter	6,400
178	SIDDHANT MANGESH DOSHI	Non - Promoter	6,400
179	ADITYA VIVEK PATKAR	Non - Promoter	6,400
180	SAMARTH MEHTA	Non - Promoter	5,500
181	RAJA JEPPEAN	Non - Promoter	5,000
182	KATTELA RAMESH	Non - Promoter	5,000
183	SAHIL MEHTA	Non - Promoter	5,000
184	SHRIKANT LAXMAN KHAJGIWALE	Non - Promoter	4,800

185	PRASANNA SHRIKANT KHAJGIWALE	Non - Promoter	4,800
186	ATUL KANTILAL SHAH	Non - Promoter	4,600
187	KETAN PRAVEEN RANGA	Non - Promoter	4,000
188	RAKESH PRAKASH SHARMA	Non - Promoter	4,000
189	THURUPHATI SHEKAR	Non - Promoter	3,200
190	KARTHIKEYAN BALAKRISHNA	Non - Promoter	3,200
191	MASILAMANI NARAYANASWAMY PONNANGATI	Non - Promoter	3,200
192	MOHAN RAO AVANURI	Non - Promoter	3,200
193	GIRIPRASAD NARAYANAN	Non - Promoter	3,200
194	KALIYUR SELVAMANI RAMANUJAM	Non - Promoter	3,200
195	ANSHUL ABHISHEK	Non - Promoter	3,200
196	LOGANATHAN MEENAKSHISUNDARAM	Non - Promoter	3,200
	TOTAL		1,61,82,800

RESOLVED FURTHER THAT in accordance with the provisions of the SEBI ICDR Regulations, the "**Relevant Date**" for the purpose of determination of the price of the equity shares to be issued and allotted as above shall be **Tuesday, April 21, 2026**, being the date 30 (thirty) days prior to the last date of Remote E-Voting i.e. the deemed date of the Postal Ballot, in accordance with Regulation 161(a) of the SEBI ICDR Regulations."

RESOLVED FURTHER THAT the Valuation Reports dated April 20, 2026, obtained by the Company from independent Registered Valuers in connection with the proposed preferential issue of equity shares on a Share Swap basis, be and are hereby noted and taken on record, particulars whereof are as follows:

(a) The valuation of equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has been carried out by Mr. Bhavesh M Rathod, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708), having his office at 12D, White Spring, A Wing, Rivali Park Complex, Western Express Highway, Borivali (East), Mumbai – 400066, who has determined the fair value of equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) at Rs. 48.15/- (Rupees Forty-Eight and Paise Fifteen Only) per equity share. Since the equity shares of the Company are infrequently traded on BSE Limited in terms of Regulation 164(5) of the SEBI ICDR Regulations, the said fair value of Rs. 48.15/- per share constitutes the floor price for the proposed preferential issue in terms of Regulation 164(2) of the SEBI ICDR Regulations.

(b) The valuation of equity shares of iSERA Biological Limited has been carried out by Mr. Karan Chetan Shah, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561), having his office at C/413, Satyam Apartment, Opposite MHB Police Station, Link Road, Borivali (West), Mumbai – 400091, who has determined the fair value of equity shares of iSERA Biological Limited at Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share, in terms of Regulation 163(3) of the SEBI ICDR Regulations.

Pursuant to the aforesaid Valuation Reports and in compliance with the provisions of Regulations 163(3), 164(2) and 166A(1) of the SEBI ICDR Regulations, the issue price for the proposed preferential allotment has been fixed at Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), which is not less than the floor

price of Rs. 48.15/- per equity share determined as aforesaid. Accordingly, the Share Swap Ratio has been determined at 1:1, being one (1) fully paid-up equity share of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) of face value Rs. 10/- each, for every one (1) equity share of iSERA Biological Limited of face value Rs. 10/- each, and the same is hereby noted and taken on record.

RESOLVED FURTHER THAT without prejudice to the generality of the above resolution, the Equity Shares proposed to be issued and allotted to the Proposed Allottees shall, inter alia, be subject to the following:

- i. The Equity Shares shall be allotted by the Company to the Proposed Allottees in dematerialised form within a period of 15 (fifteen) days from the later of: (i) date of approval of this Special Resolution; or (ii) receipt of the last of the approvals / permissions required for such allotment from any regulatory authority (including but not limited to SEBI or Stock Exchange), the In-Principle Approval of BSE Limited for issuance of the Equity Shares to the Proposed Allottees;
- ii. The Equity Shares to be issued and allotted shall be fully paid-up and shall rank pari-passu with the existing equity shares of the Company in all respects (including with respect to dividend and voting powers) from the date of allotment thereof and shall be subject to the provisions of the Memorandum of Association and Articles of Association of the Company and applicable laws;
- iii. The entire pre-preferential allotment shareholding of the Proposed Allottees, in the Company, shall be subject to lock-in for such period as specified in the provisions of Chapter V of the SEBI ICDR Regulations and any other applicable law for the time being in force
- iv. The Subscription Shares to be allotted to the Proposed Allottees shall be subject to lock-in for such period as specified in the provisions of Chapter V of the SEBI ICDR Regulations and any other applicable law for the time being in force.
- v. No partly paid-up Equity Shares shall be issued and allotted;
- vi. The Equity Shares to be issued and allotted pursuant to this preferential issue shall be listed and traded on BSE Limited, subject to the receipt of all necessary regulatory permissions, approvals and listing approval;
- vii. Since the consideration for this Preferential Issue is other than cash, there is no requirement of payment from the bank accounts of the Proposed Allottees. The consideration shall be discharged entirely by way of Transfer of the Sale Shares of iSERA Biological Limited to the Company pursuant to the Share Swap Agreement;
- viii. The Subscription Shares so offered, issued and allotted shall not exceed the number of Equity Shares as approved hereinabove.
- ix. If the Proposed Allottees fail to transfer the Sale Shares of iSERA Biological Limited to the Company, or are found ineligible for the aforesaid allotment, or upon non-receipt of necessary approval(s) of the regulatory authority(ies), as may be required and / or in accordance with the provisions of applicable law, the Company shall not allot any Equity Shares to such Proposed Allottees.

RESOLVED FURTHER THAT the Company hereby takes note of and approves the certificate from the Practicing Company Secretary confirming the compliance with Chapter V and Regulation 163(2) of the Securities Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, including amendments ("ICDR Regulations") by the Company, be and is hereby taken on record.

RESOLVED FURTHER THAT without prejudice to the generality of the above, the issue of Subscription Shares shall be subject to the terms and conditions as contained in the explanatory statement under Section 102 of the Act annexed hereto, which shall be deemed to form part hereof

RESOLVED FURTHER THAT subject to receipt of such approvals as may be required under applicable

laws, consent of the Members of the Company be and is hereby accorded to record the names and details of the Proposed Allottees in Form PAS-5 and the Board be and is hereby authorized to make an offer to the Proposed Allottees, through Letter of Offer/ Private Placement Offer Letter cum application letter in Form PAS-4 or such other form as prescribed under the Act and the SEBI ICDR Regulations. and issue a Private Placement Offer cum Application Letter in Form No. PAS-4, to the Investors inviting them to subscribe to the Equity Shares in accordance with the provisions of the Act.

RESOLVED FURTHER THAT the Board be and is hereby authorised to accept any modification(s) in terms of the issue of Equity Shares, subject to the provisions of the Act and the SEBI ICDR Regulations, without being required to seek any further consent or approval of the Members, provided that such modification(s) do not adversely affect the interest of the Members.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the Board, be and is hereby authorised on behalf of the Company to do all such other acts, deeds, matters and things as the Board may, in its absolute discretion, deem necessary or desirable for such purpose, without being required to seek any further consent or approval of the members of the Company, including but not limited to the following:

- a) To appoint and enter into arrangements with legal counsel, registrar, and other advisors necessary for the Preferential Issue, and to enter into and execute all such arrangements, contracts / agreements, memorandum, documents, etc., in connection therewith and to give them such directions or instructions as they may deem fit from time to time.
- b) To take necessary actions and steps for obtaining relevant approvals from Regulatory Authorities or such other authorities, whether regulatory or otherwise, as may be necessary in relation to the Preferential Issue; including making necessary applications and making such submissions as may be required, including applications to the BSE Limited for obtaining in-principle, listing and trading approval in connection with the Preferential Issue to be allotted pursuant to the Preferential Issue.
- c) To finalize and issue necessary offer documents including but not limited to the Letter of Offer/ Private Placement Offer Letter cum application letter in Form PAS-4 or such other form or offer document as prescribed under the Act and the SEBI ICDR Regulations, the notice of the meeting of the shareholders in connection with the Preferential Issue and to record the names of the Proposed Allottees in form PAS-5.
- d) To vary, modify or amend, in accordance with applicable law, the terms and conditions of the Preferential Issue
- e) To issue and allot subscription shares pursuant to the Preferential Issue upon receipt of the requisite approvals and the share of the iSERA Biological Limited, in accordance with the applicable laws
- f) Seek the admission of the Subscription Shares in the depository system of the National Securities Depository Limited and/or Central Depository Services (India) Limited and undertake such corporate actions as may be required in this regard.
- g) To execute the necessary documents and enter into contracts, arrangements, agreements, documents (including appointment of agencies, intermediaries, monitoring agency and advisors and any agreement or letters with the Proposed Allottees) in connection with the Preferential Issue.
- h) To settle any question, difficulty or doubt that may arise in connection with the Preferential Issue including the issuance and allotment of the Equity Shares as aforesaid and to do all such acts, deeds and things in connection therewith and incidental thereto as the Board may in its absolute discretion

consider necessary, proper, desirable or appropriate for settling such question, difficulty or doubt and making the said Preferential Issue and allotment of the Equity Shares; and to take all such steps or actions and give all such directions as may be necessary or desirable in connection with the Preferential Issue

- i) To undertake all such actions and compliances as may be necessary, desirable or expedient for the purpose of giving effect to this resolution in accordance with applicable law including the SEBI ICDR Regulations and the SEBI Listing Regulations; and
- j) To take all other steps which may be incidental, consequential, relevant or ancillary in relation to the foregoing without being required to seek any further consent or approval of the Members of the Company, and the decision of the Board shall be final and conclusive, and that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution, and the decision of the Board in relation to the foregoing shall be final and conclusive.

RESOLVED FURTHER THAT for the purpose of giving effect to the offer, issue, allotment and listing of the Equity Shares of the Company, any of the Directors or the Company Secretary of the Company be and are hereby severally authorised to do all such acts, deeds, matters and things as may be necessary, desirable or expedient for such purpose, including without limitation, preparing, signing, executing and filing applications with the appropriate authorities for obtaining requisite approvals, issuing clarifications on the issue and allotment of the Equity Shares, resolving any difficulties, effecting any modifications, changes, variations, alterations, additions and / or deletions to the foregoing as may be required by any regulatory or other authority and as the Board may in its absolute discretion deem fit and proper in the best interests of the Company, without being required to seek any further consent or approval of the Members.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the Board be and is hereby authorised to engage depositories, registrars, bankers, legal advisors and other consultants and advisors to the issue and to remunerate them by way of fees and / or other charges and also to enter into and execute all such arrangements, agreements, memoranda, documents, etc., with such agencies, as may be required and as permitted by applicable law.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the Board be and is hereby authorised to delegate any or all the powers conferred upon it by this resolution to any Committee of Directors, any Director(s), and / or officer(s) of the Company, as it may deem appropriate in the best interests of the Company."

Date: April 21, 2026

Place: Pune

By order of Board of Directors
For iSERA Lifesciences Limited
(Formerly known as Covidh Technologies Limited)

SD/-

Deepakshi
Company Secretary and Compliance Officer
Membership No.: A76335

NOTES:

The relevant Explanatory Statement pursuant to Sections 102 and 110 of the Act read with Rule 22 of the Rules, setting out the material facts and reasons for the proposed Resolutions mentioned in this Postal Ballot Notice, is appended herein below for your consideration.

- a) In compliance with the MCA Circulars, the Postal Ballot Notice along with the instructions regarding Remote E-Voting is being sent by email to all the Members, whose names appear on the Register of Members / List of Beneficial Owners as received from National Securities Depository Limited (“NSDL”) and Central Depository Services (India) Limited (“CDSL”) as on Friday, April 17, 2026 (the “Cut-Off Date”) and who have registered their email addresses in respect of electronic holdings with the Depository through the concerned Depository Participants and in respect of physical holdings with the Company’s Registrar and Share Transfer Agent, MUFG Intime India Private Limited (“RTA”).
- b) The remote e-voting period will commence on Wednesday, 22 April, 2026 (9:00 A.M. IST) and will end on Thursday, May 21, 2026 (5:00 P.M. IST). During this period, Members of the Company holding shares either in physical form or in demat form, as on the Cut-Off Date i.e., Friday, April 17, 2026, may cast their vote electronically. The e-voting module shall be disabled by MUFG Intime India Private Limited for voting thereafter and the voting shall not be allowed beyond the said date and time.
- c) The voting shall be reckoned in proportion to a Member’s share of voting rights on the paid-up share capital of the Company as on the Cut-Off Date.
- d) Pursuant to the applicable provisions of the Act and Rules framed thereunder and the Listing Regulations, the Company can serve notices and other communication through electronic mode to those Members who have registered their e-mail addresses either with the Depository Participant(s) or the Company. Members who have not registered their e-mail addresses with the Company can now register the same by sending an e-mail to the RTA at enotices@in.mpms.mufg.com. Members holding shares in demat form are requested to register their e-mail addresses with their Depository Participant(s) only.
- e) The Resolutions, if approved by the requisite majority through Postal Ballot, shall be deemed to have been duly passed on Thursday, May 21, 2026 i.e., the last date specified by the Company for receipt of votes through the Remote E-Voting process.
- f) A member cannot exercise his vote by proxy on Postal Ballot.
- g) As required by Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 read with the MCA Circulars and the Listing Regulations, the details pertaining to this Postal Ballot will be published in one English national daily newspaper circulating throughout India and one regional daily newspaper circulating in Maharashtra (in the vernacular language).
- h) In case of any query / grievance in connection with the Postal Ballot including e-voting, Members may contact MUFG Intime India Private Limited at <https://instavote.linkintime.co.in> or the Company at cscovidh@gmail.com
- i) The Postal Ballot Notice is also placed on the website of MUFG Intime India Private Limited at <https://instavote.linkintime.co.in>, on the website of BSE Limited at www.bseindia.com and on the website of the Company at www.covidhtechnologies.com. All documents referred to in the Postal Ballot Notice will be available on the Company’s website at www.covidhtechnologies.com for perusal by the Members. A copy of the new set of MOA and AOA of the Company would be available for inspection at the Registered Office of the Company during the business hours on any working day during the e-voting period. The new set of MOA and AOA will also be available electronically for inspection, to Members from the date of circulation of the Postal Ballot Notice up to the closure of the e-voting period.

Members desirous of inspecting the documents referred to in the Notice may send their requests to enotices@in.mpms.mufg.com or contact on: Tel: 022 – 4918 6000 from their registered e-mail addresses mentioning their names, folio numbers / DP ID and Client ID.

- j) Subject to the provisions of the Articles of Association of the Company, voting rights of a Member / Beneficial Owner (in case of electronic shareholding) shall be in proportion to his / her / its shareholding in the paid-up equity share capital of the Company as on the Cut-Off Date. In case of joint holders, only such joint holder who is higher in the order of names will be entitled to vote.
- k) The results of the Postal Ballot will be placed on the Company's website at www.covidhstechnologies.com and on the website of MUFG Intime India Private Limited at <https://instavote.linkintime.co.in> and will also be intimated to BSE Limited where the shares of the Company are listed, in accordance with the provisions of the Listing Regulations.

NOTICE TO SHAREHOLDERS HOLDING SHARES IN PHYSICAL MODE

SEBI has vide circular no. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/655 dated November 3, 2021, mandated furnishing of PAN, KYC and Nomination by Members holding shares in physical form. In view of the same, concerned shareholders are requested to furnish the requisite documents / information at the earliest. Non-availability of the same will result in freezing of the folios of such shareholders pursuant to the aforesaid SEBI circular. The Company has sent communications to the concerned shareholders explaining the aforesaid requirements. The necessary forms for updation of the aforementioned information are available on the website of the Company at www.covidhstechnologies.com. Members may contact the Company's RTA for assistance in this regard.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING

The remote e-voting period begins on Wednesday, 22 April, 2026 (9:00 A.M. IST) and ends on Thursday, May 21, 2026 (5:00 P.M. IST). The remote e-voting module shall be disabled by MUFG Intime India Private Limited for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (Cut-Off Date) i.e. Friday, April 17, 2026 may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the Cut-Off Date, being Friday, April 17, 2026.

In terms of SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

REMOTE E-VOTING INSTRUCTIONS:

In terms of SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access remote e-Voting facility.

Login method for Individual shareholders holding securities in demat mode:

Individual Shareholders holding securities in demat mode with NSDL

METHOD 1 – NSDL OTP based login

- a) Visit URL: <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>

- b) Enter your 8-character DP ID, 8-digit Client Id, PAN, Verification code and generate OTP.
- c) Enter the OTP received on your registered email ID / mobile number and click on login.
- d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services.
- e) Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

METHOD 2 – NSDL IDeAS facility Shareholders registered for IDeAS facility:

- a) Visit URL: <https://eservices.nsdl.com> and click on “Beneficial Owner” icon under “IDeAS Login Section”. Enter IDeAS User ID, Password, Verification code & click on “Log-in”.
- b) Post successful authentication, you will be able to see e-Voting services under Value added services section. Click on “Access to e-Voting” under e-Voting services.
- c) Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Shareholders not registered for IDeAS facility:

- a) To register, visit URL: <https://eservices.nsdl.com> and select “Register Online for IDeAS Portal” or click on <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>
- b) Enter 8-character DP ID, 8-digit Client ID, Mobile no, Verification code & click on “Submit”.
- c) Enter the last 4 digits of your bank account / generate ‘OTP’.
- d) Post successful registration, user will be provided with Login ID and password.
- e) Follow steps given above in points (a-d).

METHOD 3 – NSDL e-voting website

- a) Visit URL: <https://www.evoting.nsdl.com>
- b) Click on the “Login” tab available under ‘Shareholder/Member’ section.
- c) Enter User ID (i.e., your 16-digit demat account no. held with NSDL), Password/OTP and a Verification Code as shown on the screen & click on “Login”.
- d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services.
- e) Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Individual Shareholders holding securities in demat mode with CDSL

METHOD 1 – CDSL e-voting page

- a) Visit URL: <https://www.cdslindia.com>.
- b) Go to e-voting tab.
- c) Enter 16-digit Demat Account Number (BO ID) and PAN No. and click on “Submit”.
- d) System will authenticate the user by sending OTP on registered Mobile and Email as recorded in Demat Account.
- e) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on “MUFG InTime” or “evoting link displayed alongside

Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

METHOD 2 – CDSL Easi / Easiest facility:

Shareholders registered for Easi / Easiest facility:

- a) Visit URL: <https://web.cdslindia.com/myeasitoken/Home/Login> or Visit URL: www.cdslindia.com, click on "Login" and select "My Easi New (Token)".
- b) Enter existing username, Password & click on "Login".
- c) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Shareholders not registered for Easi / Easiest facility:

- a) To register, visit URL: <https://web.cdslindia.com/myeasitoken/Home/EasiRegistration> / <https://web.cdslindia.com/myeasitoken/Home/EasiestRegistration>.
- b) Proceed with updating the required fields for registration.
- c) Post successful registration, user will be provided username and password on the registered email id. Follow steps given above in points (a-c).

Individual Shareholders holding securities in demat mode with Depository Participant

Individual shareholders can also login using the login credentials of your demat account through your depository participant registered with NSDL / CDSL for e-voting facility.

- a) Login to DP website.
- b) After Successful login, user shall navigate through "e-voting" option.
- c) Click on e-voting option, user will be redirected to NSDL / CDSL Depository website after successful authentication, wherein user can see e-voting feature.
- d) Post successful authentication, click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Login method for shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode.

Shareholders holding shares in physical mode / Non-Individual Shareholders holding securities in demat mode as on the Cut-Off Date for e-voting may register and vote on InstaVote as under:

STEP 1: LOGIN / SIGNUP on InstaVote Shareholders registered for INSTAVOTE facility:

- a) Visit URL: <https://instavote.linkintime.co.in> & click on "Login" under 'SHARE HOLDER' tab.
- b) Enter details as under:
- c) User ID: Enter User ID
- d) Password: Enter existing Password
- e) Enter Image Verification (CAPTCHA) Code
- f) Click "Submit".

(Home page of e-voting will open. Follow the process given under "Steps to cast vote for Resolutions")

STEP 2: Steps to cast vote for Resolutions through InstaVote

- a) Post successful authentication and redirection to InstaVote inbox page, you will be able to see the “Notification for e-voting”.
- b) Select ‘View’ icon. E-voting page will appear.
- c) Refer the Resolution description and cast your vote by selecting your desired option ‘Favour / Against’ (If you wish to view the entire Resolution details, click on the ‘View Resolution’ file link).
- d) After selecting the desired option i.e. Favour / Against, click on ‘Submit’.
- e) A confirmation box will be displayed. If you wish to confirm your vote, click on ‘Yes’, else to change your vote, click on ‘No’ and accordingly modify your vote.

NOTE: Shareholders may click on “Vote as per Proxy Advisor’s Recommendation” option and view proxy advisor recommendations for each resolution before casting vote. “Vote as per Proxy Advisor’s Recommendation” option provides access to expert insights during the e-Voting process. Shareholders may modify their vote before final submission.

Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently.

Non-Individual Body corporate shareholders shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at www.covidhtechnologies.com.

Guidelines for Institutional shareholders (“Custodian / Corporate Body / Mutual Fund”)

STEP 1 – Custodian / Corporate Body / Mutual Fund Registration

- a) Visit URL: <https://instavote.linkintime.co.in>
- b) Click on “Sign Up” under “Custodian / Corporate Body / Mutual Fund”.
- c) Fill up your entity details and submit the form.
- d) A declaration form and organization ID is generated and sent to the Primary contact person email ID (which is filled at the time of sign up). The said form is to be signed by the Authorised Signatory, Director, Company Secretary of the entity & stamped and sent to insta.vote@linkintime.co.in.
- e) Thereafter, Login credentials (User ID; Organisation ID; Password) is sent to Primary contact person’s email ID. (You have now registered on InstaVote.)

STEP 2 – Investor Mapping

- a) Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- b) Click on “Investor Mapping” tab under the Menu section.
- c) Map the Investor with the following details:
 1. ‘Investor ID’ – Investor ID for NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID i.e., IN00000012345678; Investor ID for CDSL demat account is 16 Digit Beneficiary ID.
 2. ‘Investor’s Name – Enter Investor’s Name as updated with DP.
 3. ‘Investor PAN’ – Enter your 10-digit PAN.
 4. ‘Power of Attorney’ – Attach Board resolution or Power of Attorney.

NOTE: File Name for the Board resolution / Power of Attorney shall be – DP ID and Client ID or 16 Digit

Beneficiary ID.

Further, Custodians and Mutual Funds shall also upload specimen signatures.

- d) Click on Submit button. (The investor is now mapped with the Custodian / Corporate Body / Mutual Fund Entity). The same can be viewed under the “Report section”.

STEP 3 – Steps to cast vote for Resolutions through InstaVote

The corporate shareholder can vote by two methods, during the remote e-voting period.

METHOD 1 – VOTES ENTRY

- a) Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- b) Click on “Votes Entry” tab under the Menu section.
- c) Enter the “Event No.” for which you want to cast vote.
- d) Event No. can be viewed on the home page of InstaVote under “On-going Events”.
- e) Enter “16-digit Demat Account No.”.
- f) Refer the Resolution description and cast your vote by selecting your desired option ‘Favour / Against’ (If you wish to view the entire Resolution details, click on the ‘View Resolution’ file link). After selecting the desired option i.e. Favour / Against, click on ‘Submit’.
- g) A confirmation box will be displayed. If you wish to confirm your vote, click on ‘Yes’, else to change your vote, click on ‘No’ and accordingly modify your vote.
(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

METHOD 2 – VOTES UPLOAD

- a) Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- b) After successful login, you will see “Notification for e-voting”.
- c) Select “View” icon for “Company’s Name / Event number”.
- d) E-voting page will appear.
- e) Download sample vote file from “Download Sample Vote File” tab.
- f) Cast your vote by selecting your desired option ‘Favour / Against’ in the sample vote file and upload the same under “Upload Vote File” option.
- g) Click on ‘Submit’. ‘Data uploaded successfully’ message will be displayed.
(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

NOTE: Non-Individual Body corporate shareholders shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at _____.

HELPDESK:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode facing any technical issue in login may contact INSTAVOTE helpdesk by sending a request at enotices@in.mpms.mufg.com or contact on: Tel: 022 – 4918 6000.

Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in demat mode may contact the respective helpdesk for any technical issues related to login through Depository i.e., NSDL and CDSL.

Login Type	Helpdesk Details
Physical mode / Non-Individual Shareholders in demat mode	Email: enotices@in.mpms.mufg.com Tel: 022 – 4918 6000
Individual Shareholders with NSDL	Email: evoting@nsdl.co.in Tel: 022 - 4886 7000
Individual Shareholders with CDSL	Email: helpdesk.evoting@cdslindia.com Toll Free: 1800 22 55 33

Forgot Password:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both then the shareholder can use the “Forgot Password” option available on: <https://instavote.linkintime.co.in>

- Click on “Login” under ‘SHARE HOLDER’ tab.
- Further Click on “forgot password?”
- Enter User ID, select Mode and Enter Image Verification code (CAPTCHA).
- Click on “SUBMIT”.

In case Custodian / Corporate Body / Mutual Fund has forgotten the USER ID [Login ID] or Password or both then

the shareholder can use the “Forgot Password” option available on: <https://instavote.linkintime.co.in>

- Click on ‘Login’ under “Custodian / Corporate Body / Mutual Fund” tab.
- Further Click on “forgot password?”
- Enter User ID, Organization ID and Enter Image Verification code (CAPTCHA).
- Click on “SUBMIT”.

In case shareholders have a valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing information about the particulars of the Security Question and Answer, PAN, DOB / DOI etc. The password should contain a minimum of 8 characters, at least one special character (!#\$%&*), at least one numeral, at least one alphabet and at least one capital letter.

Individual Shareholders holding securities in demat mode with NSDL / CDSL has forgotten the password:

Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both, then the Shareholders are advised to use Forget User ID and Forget Password option available at above mentioned depository / depository participants website.

General Instructions – Shareholders

- It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- For shareholders / members holding shares in physical form, the details can be used only for voting on

the resolutions contained in this Notice.

- During the voting period, shareholders / members can login any number of time till they have voted on the resolution(s) for a particular “Event”.

Date: April 21, 2026

Place: Pune

By order of Board of Directors
For iSERA Lifesciences Limited
(Formerly known as Covidh Technologies Limited)

SD/-

Deepakshi
Company Secretary and Compliance Officer
Membership No.: A76335

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) AND SECTION 110 OF THE COMPANIES ACT, 2013 AND REGULATION 163 OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

Item No. 1: INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY AND CONSEQUENTIAL ALTERATION IN CAPITAL CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY

The Board of Directors of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) (“the Company”) at its meeting held on Tuesday, April 21, 2026, proposed an increase in the Authorised Share Capital of the Company from Rs. 11,00,00,000/- (Rupees Eleven Crore Only) divided into 1,10,00,000 (One Crore Ten Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 25,00,00,000/- (Rupees Twenty-Five Crore Only) divided into 2,50,00,000 (Two Crore Fifty Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each, subject to the approval of the Members of the Company.

It is therefore proposed to increase the Authorised Share Capital of the Company by creating 1,40,00,000 (One Crore Forty Lakh) additional Equity Shares of Rs. 10/- (Rupees Ten Only) each, ranking pari-passu with the existing Equity Shares in all respects, in accordance with the Memorandum and Articles of Association of the Company.

As per the provisions of Sections 13 and 61 of the Companies Act, 2013 read with the Companies (Share Capital and Debentures) Rules, 2014, the approval of the shareholders by way of an Ordinary Resolution is required for the alteration of the Capital Clause of the Memorandum of Association consequent upon the increase in Authorised Share Capital of the Company.

A copy of the Memorandum of Association of the Company showing the proposed changes will be available for inspection by the Members at the Registered Office of the Company during business hours on all working days up to the date of closure of remote e-voting.

Accordingly, the Board recommends the Ordinary Resolution set out at Item No. 1, seeking the approval of the Members for increasing the Authorised Share Capital of the Company and consequential alteration of Clause V of the Memorandum of Association.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives are in any way concerned or interested, financially or otherwise, in the said resolution, except to the extent of their respective shareholding in the Company, if any.

Item No. 2: ADOPTION OF NEW SET OF MEMORANDUM OF ASSOCIATION OF THE COMPANY AS PER THE PROVISIONS OF THE COMPANIES ACT, 2013, IN SUBSTITUTION OF THE EXISTING MEMORANDUM OF ASSOCIATION

The existing Memorandum of Association (“MOA”) of the Company has been framed in accordance with the provisions of the Companies Act, 1956 (the “erstwhile Act”) and is required to be aligned with the provisions of the Companies Act, 2013 and the rules made thereunder. Accordingly, the alteration and adoption of a new set of MOA is necessary to ensure conformity with the Companies Act, 2013. The existing MOA is therefore proposed to be re-aligned in accordance with Table A of Schedule I of the Companies Act, 2013.

Accordingly, the Board of Directors of the Company has considered and approved the adoption of a new set of Memorandum of Association in substitution of and to the entire exclusion of the existing Memorandum of Association, in conformity with the Companies Act, 2013, subject to the approval of the Members by way of a Special Resolution.

A copy of the new set of Memorandum of Association is available for inspection by the Members at the Registered Office of the Company during business hours on all working days up to the date of closure of remote e-voting. The details of the alterations in the MOA are described in Annexure-A to the Board

Outcome.

Accordingly, the Board recommends the Special Resolution set out at Item No. 2, seeking the approval of the Members for the adoption of the new set of Memorandum of Association as per Companies Act 2013.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives are in any way concerned or interested, financially or otherwise, in the said resolution.

Item No. 3: ADOPTION OF NEW SET OF ARTICLES OF ASSOCIATION OF THE COMPANY AS PER THE PROVISIONS OF THE COMPANIES ACT, 2013, IN SUBSTITUTION OF THE EXISTING ARTICLES OF ASSOCIATION

The existing Articles of Association (“AOA”) of the Company are framed under the provisions of the Companies Act, 1956 (the “erstwhile Act”) and several regulations in the existing AOA contain references to specific sections of the erstwhile Act. Some provisions in the existing AOA are no longer in conformity with the Companies Act, 2013 (the “new Act”) and the rules framed thereunder. In order to bring the existing AOA in line with the provisions of the Companies Act 2013, the Company would be required to make changes in the existing AOA. It is therefore considered necessary and desirable to adopt a comprehensive new set of Articles of Association of the Company in substitution of and to the entire exclusion of the existing Articles of Association.

The new AOA to be substituted in place of the existing AOA are based on Table F of the Companies Act, 2013, which sets out the model Articles of Association for a company limited by shares.

A copy of the new set of Articles of Association is available for inspection by the Members at the Registered Office of the Company during business hours on all working days up to the date of closure of remote e-voting. The details of the alterations in the AOA are described in Annexure-A to the Board Outcome.

Accordingly, the Board recommends the Special Resolution set out at Item No. 3, seeking the approval of the Members for the adoption of the new set of Articles of Association as per Companies Act 2013.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives are in any way concerned or interested, financially or otherwise, in the said resolution.

Item No. 4: ENHANCEMENT OF LIMITS FOR MAKING INVESTMENTS, GIVING LOANS OR GUARANTEES AND PROVIDING SECURITIES UNDER SECTION 186 OF THE COMPANIES ACT, 2013

As per the provisions of Section 186 read with Section 179(3)(f) of the Companies Act, 2013, read with the Companies (Meetings of Board and its Powers) Rules, 2014, as amended, no company is permitted to, directly or indirectly:

- a. Give any loan to any person or other body corporate;
- b. Give any guarantee or provide security in connection with a loan to any other body corporate or person; and
- c. Acquire by way of subscription, purchase or otherwise, the securities of any other body corporate,

exceeding sixty percent of its paid-up share capital, free reserves and securities premium account or one hundred per cent of its free reserves and securities premium account, whichever is more. The said Section further provides that where the giving of any loan or guarantee or providing any security or the acquisition exceeds the limits specified therein, prior approval of the Members by means of a Special Resolution is required to be passed at a general meeting.

In view of the above and considering the long-term business plans of the Company, including the proposed acquisition of iSERA Biological Limited and future investments and expansions, which would require the

Company to make sizeable loans / investments and issue guarantees / securities to persons or body corporates from time to time, the prior approval of the Members is being sought for enhancement of the aggregate limit up to Rs. 1,000,00,00,000/- (Rupees One Thousand Crore Only) outstanding at any point of time.

The Board confirms that there is no subsisting default in repayment of any deposit or interest thereon, and that prior approval of the Public Financial Institutions, wherever required, shall be obtained as required under Section 186(5) of the Companies Act, 2013.

Accordingly, the Board recommends the Special Resolution set out at Item No. 4, seeking the approval of the Members by way of a Special Resolution.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives are in any way concerned or interested, financially or otherwise, in the said resolution, except to the extent of their respective shareholding in the Company, if any.

Item No. 5: APPROVAL OF RELATED PARTY TRANSACTION – ACQUISITION OF UP TO 100% EQUITY SHAREHOLDING OF iSERA BIOLOGICAL LIMITED THROUGH SHARE SWAP

iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has its equity shares listed on BSE Limited. As on the last day of the previous financial year (March 31, 2025), the paid-up equity share capital of the Company was Rs. 32,34,220/- (i.e., less than Rs. 10 Crore) and the net worth of the Company did not exceed Rs. 25 Crore. In terms of Regulation 15(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the corporate governance provisions, including Regulation 23 pertaining to Related Party Transactions, are not applicable to a listed entity having paid-up equity share capital not exceeding Rs. 10 Crore and net worth not exceeding Rs. 25 Crore as on the last day of the previous financial year. Accordingly, the provisions of Regulations 17 to 27 of the SEBI Listing Regulations, including Regulation 23 governing Related Party Transactions, are presently not applicable to the Company.

Notwithstanding the above, as mandated by Regulation 15(3) of the SEBI Listing Regulations, the provisions of the Companies Act, 2013 continue to apply to the Company wherever applicable. The proposed transaction is accordingly governed by Section 188 read with Section 177 of the Companies Act, 2013, and the Rules made thereunder, including the Companies (Meetings of Board and its Powers) Rules, 2014.

Further, the Board of Directors of the Company has, in exercise of its powers under the Companies Act, 2013, adopted a **Policy on Materiality of Related Party Transactions and Dealing with Related Party Transactions** ("RPT Policy"). The Company's RPT Policy, which has been framed in alignment with good corporate governance principles and best practices, incorporates disclosure and approval standards in line with the philosophy of Regulation 23 of the SEBI Listing Regulations – including the materiality threshold, Audit Committee review, shareholder approval for material transactions, and the restriction on related parties from voting on such resolutions. The Company has chosen to adopt these higher governance standards voluntarily in the interest of transparency and investor protection.

Since the proposed acquisition constitutes a Material Related Party Transaction within the meaning of the Company's RPT Policy and also triggers the threshold requiring shareholder approval under Section 188 of the Companies Act, 2013 (as the paid-up share capital of the Company is Rs. 8,40,89,720/- which is not less than Rs. 10 Crore once the proposed issue is completed and also in view of the value of the proposed transaction in relation to the Company's net worth and turnover), the approval of the Members is being sought by way of a Ordinary Resolution.

Background and Transaction Details:

The Members are informed that, pursuant to the prior approval and recommendation of the Audit Committee of the Company (comprising only Independent Directors), at its meeting held on Monday, April 20, 2026, the Board of Directors of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), at their meeting held on Monday, April 20, 2026, considered and approved the acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited, an unlisted public company (CIN: U85300PN2016PLC165483), incorporated on July 13, 2016, having its registered office at Flat-504, Bldg-A, S. No. 671/2A/3, Bibwewadi, Pune, Maharashtra – 411037, from the existing shareholders of iSERA Biological Limited, who are related parties of the Company under Section 2(76) of the Companies Act, 2013, for a total non-cash consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), to be discharged entirely by way of issuance and allotment of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of the Company at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share, being not less than the floor price of Rs. 48.15/- per equity share determined in accordance with Regulation 164(2) of Chapter V of the SEBI ICDR Regulations, on a preferential basis for consideration other than cash (Share Swap). Upon completion of the said acquisition, iSERA Biological Limited shall become a Wholly Owned Subsidiary of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited).

The said transaction constitutes a Related Party Transaction within the meaning of Section 2(76) of the Companies Act, 2013 and the Company's RPT Policy, since the Promoter / Promoter Group of the Company are the Director(s)/ Shareholder(s) of iSERA Biological Limited. The transaction has been undertaken on an arm's length basis, as certified by the Registered Valuer in the Valuation Report dated Monday, 20 April, 2026.

Accordingly, the approval of the Members of the Company is being sought by way of a Ordinary Resolution, as required under Section 188 of the Companies Act, 2013 read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, and in accordance with the Company's Policy on Materiality of Related Party Transactions.

Details of the Related Party Transaction as required under the Company's RPT Policy and Section 188 of the Companies Act, 2013:

Sr. No.	Particulars	Details
1.	Type, material terms and particulars of the proposed transaction	Acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited from its existing shareholders, who are related parties of the Company, for a total non-cash consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), to be discharged by way of issuance and allotment of equity shares of the Company on a preferential basis in terms of the SEBI ICDR Regulations, at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share, pursuant to the Valuation Reports dated April 20, 2026, issued by Mr. Bhavesh M Rathod, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708) in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), and Mr. Karan Chetan Shah, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561) in respect of iSERA Biological Limited. Consequent to the Board approval, a Share Swap Agreement has been / shall be executed between the Company and the shareholders of iSERA Biological Limited. The transaction is conditional upon Members' approval and receipt of In-Principle Approval from BSE Limited.
2.	Name of the related party and its relationship with the listed entity	iSERA Biological Limited and its shareholders (including Promoter / Promoter Group of iSERA Lifesciences Limited) are related parties of the Company under Section 2(76) of the Companies Act, 2013 and the Company's Policy on Materiality of Related Party Transactions.
3.	Tenure of the proposed transaction	Not applicable. The allotment of equity shares of the Company shall be completed within 15 (fifteen) days from the later of: (i) receipt of Members' approval; or (ii) receipt of In-Principle Approval from BSE Limited and such other regulatory approvals as may be required.
4.	Value of the proposed transaction	Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only)
5.	Details regarding loans / inter-corporate deposits / investments	Not applicable. The consideration for this transaction shall be discharged entirely by way of issuance and allotment of equity shares of the Company on a preferential basis. No cash outflow is involved.

6.	Justification as to why the RPT is in the interest of the listed entity	The acquisition of up to 100% equity shareholding of iSERA Biological Limited is in line with the Company's strategic vision to expand and consolidate its presence in the pharmaceutical and life sciences sector. iSERA Biological Limited is engaged in the manufacture, import, export and trading of pharmaceutical, biological and biotechnological products. The business activities of iSERA Biological Limited complement the overall business profile of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), and the acquisition shall enable the Company to create synergistic value for its Members. The transaction shall be effected through a non-cash share swap, thereby preserving the Company's liquidity and optimising use of available resources.
7.	Valuation or other external party report relied upon	The valuation reports dated Monday, 20 April, 2026 for of iSERA Lifesciences Limited and iSERA Biological Limited have been duly obtained from independent registered valuers. The valuation of iSERA Lifesciences Limited has been carried out by Mr. Bhavesh M. Rathod, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708), having his address at 12D, White Spring, A Wing, Rivali Park Complex, Western Express Highway, Borivali (East), Mumbai – 400066. Further, the valuation of iSERA Biological Limited has been conducted by Mr. Karan Chetan Shah, Registered Valuer (IBBI Registration No. Reg No: IBBI/RV/06/2024/15561), having his address at C/413, Satyam Apartment, Opposite MHB Police Station, Link Road, Borivali (West), Mumbai – 400091.
8.	Any other information that may be relevant	All relevant and important information forms part of this Explanatory Statement. In terms of the Company's RPT Policy – which incorporates the spirit and principles of Regulation 23 of the SEBI Listing Regulations on a voluntary basis – all related parties, whether or not party to this transaction, shall not vote to approve this resolution. None of the Directors or Key Managerial Personnel of the Company (other than those who are shareholders of iSERA Biological Limited) or their relatives are concerned or interested in this resolution, except to the extent of their shareholding in the Company, if any.

The Board of Directors accordingly recommends the Ordinary Resolution set out at Item No. 5, seeking the approval of the Members.

The Directors who are shareholders of iSERA Biological Limited and therefore related parties, namely Shubhangi Dhanraj Garad, Sumeet Dhanraj Garad, Pratap Dadasaheb Deshmukh, Ritu Dhanraj Garad, Archana Kakasaheb Lonkar, Nandkumar Subhash Kadam and Dhairyasheel Vasantrao Yadav, are interested in this resolution. No related party shall be entitled to vote on this resolution.

Item No. 6: ACQUISITION OF UP TO 100% EQUITY SHAREHOLDING OF iSERA BIOLOGICAL LIMITED THROUGH SHARE SWAP

The Company proposes to acquire up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares of iSERA Biological Limited, representing up to 100% of its paid-up equity share capital.

The total purchase consideration for this acquisition is Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share, as determined by the Valuation Reports dated April 20, 2026, issued by Mr. Bhavesh M Rathod, an independent Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708) in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), and Mr. Karan Chetan Shah, an independent Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561) in respect of iSERA Biological Limited. In consideration of this acquisition, the Company intends to issue and allot up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of the Company having face value of Rs. 10/- (Rupees Ten Only) each, at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share (including a premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty Only) per share), to the shareholders of iSERA Biological Limited by way of Share Swap, thereby discharging the entire Purchase Consideration. Upon completion of this acquisition, iSERA Biological Limited shall become a Wholly Owned Subsidiary of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited).

The proposed acquisition is a strategic initiative aimed at expanding the Company's presence in the pharmaceutical and life sciences sector. This acquisition will facilitate the transfer of ownership without impacting the Company's cash reserves, thereby preserving liquidity and optimising the use of available resources. The Board of Directors believes that this acquisition aligns with the Company's growth strategy and is in the best interests of the Company and its shareholders.

Accordingly, the Board recommends the Special Resolution set out at Item No. 6, seeking the approval of the Members by way of a Special Resolution under Section 186 read with Section 179(3)(j) of the Companies Act, 2013.

The Directors who are shareholders of iSERA Biological Limited, namely Shubhangi Dhanraj Garad, Sumeet Dhanraj Garad, Pratap Dadasaheb Deshmukh, Ritu Dhanraj Garad, Archana Kakasaheb Lonkar, Nandkumar Subhash Kadam and Dhairyasheel Vasantrao Yadav, may be deemed to be interested in the said resolution. None of the other Directors or Key Managerial Personnel of the Company or their relatives are in any way concerned or interested, financially or otherwise, in the said resolution, except to the extent of their respective shareholding in the Company, if any.

Item No. 7: ISSUANCE OF EQUITY SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS FOR CONSIDERATION OTHER THAN CASH (SHARE SWAP)

The Board, pursuant to its resolution dated Tuesday, April 21, 2026, approved the acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited, against issuance of up to 1,61,82,800 (One Crore Sixty- One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) to the shareholders of iSERA Biological Limited by way of Share Swap.

All 196 (One Hundred and Ninety-Six) proposed allottees, being the existing shareholders of iSERA Biological Limited, have confirmed their eligibility in terms of Regulation 159 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") to subscribe to the equity shares to be issued pursuant to this Preferential Issue.

In accordance with Sections 23, 42, 62(1)(c) and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) and the rules made thereunder and in accordance with the SEBI ICDR Regulations and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time, approval of the Members of the Company by way of a Special Resolution is required to issue equity shares by way of private placement on a preferential basis for consideration other than cash.

The preferential issue shall be made in terms of Chapter V of the SEBI ICDR Regulations and applicable provisions of the Companies Act, 2013. The said proposal has been considered and approved by the Board at its meeting held on Tuesday, April 21, 2026.

The relevant disclosures as required in terms of the Act and the SEBI ICDR Regulations, as amended from time to time, are as under:

a) Objects of the Preferential Issue:

The Company intends to acquire up to 100% of the paid-up equity share capital of iSERA Biological Limited (CIN: U85300PN2016PLC165483). The purchase consideration payable for the said acquisition shall be discharged entirely by allotment of up to 1,61,82,800 equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) to the shareholders of iSERA Biological Limited for consideration other than cash (Share Swap), subject to the SEBI ICDR Regulations and receipt of requisite **approvals from BSE Limited and such other regulatory authorities as may be applicable.**

b) Monitoring of Utilization of Funds:

In terms of Regulation 162A(1) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, an issuer is required to appoint a SEBI-registered credit rating agency to monitor the utilisation of issue proceeds where the size of the issue exceeds ₹100 crore. However, in the present case, the proposed preferential allotment of equity shares is below the aforesaid threshold and is being undertaken pursuant to a share swap arrangement, involving consideration other than cash. Accordingly, *Appointment of Monitoring agency for Utilization of Funds is not applicable in our case.*

c) Particulars of the offer including the maximum number of specified securities to be issued:

The Board, pursuant to its resolution dated Monday, April 20, 2026, has approved the proposed preferential issue of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value Rs. 10/- (Rupees Ten Only) each, at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share (including a premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty Only) per share), for consideration other than cash (Share Swap), aggregating to a total consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only).

d) Relevant Date with reference to which the price has been arrived at:

In terms of the provisions of Chapter V of the SEBI ICDR Regulations, the Relevant Date for determining the minimum issue price of equity shares shall be Tuesday, April 21, 2026 (i.e., the date of the Board Meeting at which the preferential issue was approved, being 30 days prior to the last date of Remote E-Voting / deemed date of the General Meeting, i.e., Thursday, 21 May, 2026), in accordance with Regulation 161(a) of the SEBI ICDR Regulations.

e) Amount which the Company intends to raise by way of such securities:

The shares are being allotted for consideration other than cash as part of the consideration payable towards the acquisition of iSERA Biological Limited. No cash consideration will be received by the Company.

f) Basis on which the price has been arrived at and justification for the price (including premium, if any):

The equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) are listed on BSE Limited ("BSE"). The equity shares of the Company are infrequently traded on BSE in terms of Regulation 164(5) of the SEBI ICDR Regulations.

Accordingly, in the case of infrequently traded shares, as per Regulation 164(2) of the SEBI ICDR Regulations, the price of the equity shares to be allotted on a preferential basis shall not be less than the higher of:

- a) The price determined by the acquirer and the issuer taking into account the valuation parameters including book value, comparable trading multiples, and such other parameters as are customary for valuation of shares of such companies; and
- b) The price as determined in accordance with the provisions of any regulations framed under the Securities and Exchange Board of India Act, 1992, as may be applicable.

Accordingly, since the proposed allotment is for consideration other than cash (Share Swap) and involves allotment of more than 5% of the post-issue fully diluted share capital of the Company, the Company is required to obtain a Valuation Report from an independent Registered Valuer in terms of Regulation 166A(1) of the SEBI ICDR Regulations.

The Company has obtained Valuation Reports dated April 20, 2026, issued by Mr. Bhavesh M Rathod, an independent Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708) in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), and Mr. Karan Chetan Shah, an independent Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561) in respect of iSERA Biological Limited, in accordance with Regulations 163(3), 164(2), 165 and 166A of the SEBI ICDR Regulations. The Valuation Reports shall be available for inspection by the Members and the same may be accessed on the Company's website at www.covidhtechnologies.com.

Price determined as per Regulation 164(2) (Valuation Report — fair value of iSERA Lifesciences Limited for infrequently traded shares): Rs. 48.15/- per equity share.

Price determined as per Regulation 166A(1) (Valuation Report — fair value of iSERA Biological Limited for non-cash consideration / Swap Ratio): Rs. 48.20/- per equity share.

Accordingly, the equity shares shall be issued at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share of face value Rs. 10/- (Rupees Ten Only) each (including a premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty Only) per share), being not less than the floor price of Rs. 48.15/- per equity share as determined under the applicable provisions of the SEBI ICDR Regulations.

g) Intent of the Promoters, Directors, Key Managerial Personnel or Senior Management of the Company to subscribe to the Preferential Offer:

The following Promoters and Directors of the Company, who are also shareholders of iSERA Biological Limited, intend to subscribe to the equity shares under the Preferential Issue (as shareholders of iSERA Biological Limited and not in their capacity as Promoters / Directors of the Company):

Sr. No.	Name	Designation	Pre-Issue Shares Held in iSERA Lifesciences Limited	No. of Equity Shares to be Allotted under Preferential Issue
1.	Shubhangi Dhanraj Garad	Promoter	8,00,000	27,55,000
2.	Sumeet Dhanraj Garad	Promoter	1,00,000	11,92,000
3.	Pratap Dadasaheb Deshmukh	Promoter & Director	5,50,000	7,85,500
4.	Ritu Dhanraj Garad	Promoter & Director	1,00,000	7,46,000
5.	Archana Kakasaheb Lonkar	Promoter	7,00,000	4,95,000
6.	Nandkumar Subhash Kadam	Promoter & Director	11,15,000	4,56,500
7.	Dhairyasheel Vasant Rao Yadav	Promoter & Director	11,15,000	4,50,50
8.	Jitendra Prabhakar Nene	Director	Nil	10,000
9.	Mangina Srinivas Rao	Director	10,000	41,600

Save as above, none of the other Promoters, Directors, Key Managerial Personnel or Senior Management of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) intend to subscribe to the equity shares under the Preferential Issue.

h) Shareholding Pattern of the Company before and after the Preferential Issue:

The shareholding pattern of the Company before and after the proposed Preferential Issue is as under:

Sr. No.	Category	Pre-Issue Shareholding		Post Issue Shareholding#	
		No. of equity shares held	% of Shares	No. of equity shares held	% of Shares*
A	Promoter & Promoter Group Shareholding				
A1	Indian Promoter	49,30,000	58.63%	1,35,43,000	55.07%
A2	Foreign Promoter	0	0.00%	0	0.00%
	Sub Total (A)	49,30,000	58.63%	1,35,43,000	55.07%
B	Public Shareholding				
B1	Institutions	0	0.00%	0	0.00%
B2	Institutions (Domestic)	0	0.00%	0	0.00%
	Mutual Funds	0	0.00%	0	0.00%
B3	Institutions (Foreign)	0	0.00%	0	0.00%
B4	Central Government/ State	0	0.00%	0	0.00%
	Government(s)/ President of India				

B5	Non-Institutions				
	Directors and their relatives (excluding independent directors and nominee directors)	0	0.00%	10,000	0.04%
	Key Managerial Personnel	0	0.00%	0	0.00%
	Resident Individuals holding nominal share capital up to Rs. 2 lakhs	10,63,687	12.65%	18,77,087	7.63%
	Resident Individuals holding nominal share capital in excess of Rs. 2 lakhs	19,38,189	23.05%	49,29,990	20.05%
	Non-Resident Indians (NRIs)	100183	1.19%	1039183	4.23%
	Foreign Companies	0	0.00%	0	0.00%
	Bodies Corporate	303288	3.61%	11,11,288	4.52%
	Any Other (specify) [HUF, Partnership Firm, Foreign Fund Entities (VCC/PCC)]	73,624	0.88%	20,81,224	8.46%
	Sub Total B= B1+B2+B3+B4+B5	34,78,971	41.37%	1,10,48,772	44.93%
	Total Shareholding (A+B)	84,08,971	100.00%	2,45,91,772	100.00%

(*) The post-issue shareholding pattern figures are based on the assumption that all 1,61,82,800 equity shares proposed under this Preferential Issue will be allotted in full. In case of partial allotment, the figures will vary accordingly.

i) Time frame within which the Preferential Issue shall be completed:

As required under Chapter V of the SEBI ICDR Regulations, the Company shall complete the allotment of Equity Shares on or before the expiry of 15 (Fifteen) days from the later of: (i) the date of passing of the Special Resolution by the Members granting consent for the Preferential Issue; or (ii) receipt of In-Principle Approval from BSE Limited and such other regulatory approvals as may be required for the allotment; whichever is later.

j) Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees:

Out of 196 proposed allottees, the majority are natural persons and hence are themselves the ultimate beneficial owners. The details of non-individual allottees requiring UBO disclosure are as under:

Sr. No	Name of the Proposed Allottee	Category (Pre-Issue)	Name of the Ultimate Beneficial Owner	Pre-Issue Holding		No. of Equity Shares Proposed to be Allotted	Post-Issue Holding	
							No. of Equity Shares	% of Holdings
1	NAV CAPITAL	Non-Promote	Veerendra Chandalad	Nil	—	10,00,000	10,00,000	4.07%

	VCC – NAV CAPITAL EMERGING STAR FUND	r	a					
2	M7 GLOBAL FUND PCC – CELL DEWCAP FUND	Non- Promote r	1. Nikhil Kumar 2. Low Ren Feng	Nil	—	4,24,800	4,24,800	1.73%
3	DOVETAIL GLOBAL FUND PCC ALL SEASONS INDIA OPPORTUNI TI ES FUND	Non- Promote r	1. Ishtiyaak Rajubally 2. Samir Khatri 3. Patrick Derek Wong Wan Po	Nil	—	1,50,000	1,50,000	0.61%
4	MORDE FOODS PRIVATE LIMITED	Non- Promote r	1. Chandraka nt Morde 2. Sudhir Morde 3. Kishor Morde 4. Harshal Morde	Nil	—	2,00,00 0	2,00,00 0	0.81%
5	ERINOME ADVISORS LLP	Non- Promote r	1. Shabnam Alvi Gandi 2. Jai Gaurang Gandi	Nil	—	2,00,00 0	2,00,00 0	0.81%
6	EUDORA VENTURES LLP	Non- Promote r	1. Harish Shah 2. Bina Shah 3. Amira Shah Chhabra	Nil	—	1,50,000	1,50,000	0.61%
7	FAT PANDA REALTY LLP	Non- Promote r	1. Rahul Mehta 2. Sarfaraz Naviwala 3. Asmaa Sarfaraz Naviwala 4. Priyanka Rahul	Nil	—	1,30,000	1,30,000	0.53%

			Mehta					
8	3STATE VENTURES PTE. LTD.	Non-Promoter	Binny Bansal	Nil	—	1,00,000	1,00,000	0.41%
9	Rex Equity	Non-Promoter	1. Rohan Pai 2. Vinay Pai 3. Asmita Pai 4. Rashmi Joshi	Nil	—	83,200	83,200	0.34%
10	NETRADEEP EYE HOSPITAL PRIVATE LTD	Non-Promoter	1. Vasantbhai Sapovadia 2. Premji 3. Shobhnaben Sapovadia 4. Aditi Bhavin Tilva 5. Avani Jasani	Nil	—	41,600	41,600	0.17%
11	SAROD REALITY PRIVATE LIMITED	Non-Promoter	Salil Taneja	Nil	—	41,600	41,600	0.17%
12	DEEPAK AGASHE HUF	Non-Promoter	Deepak Agashe (Karta)	Nil	—	1,41,600	1,41,600	0.58%
13	AMIT J DHOLAKIA HUF	Non-Promoter	Amit Dholakia (Karta)	Nil	—	1,00,000	1,00,000	0.41%
14	KINGSMAN WEALTH MANAGEMENT PRIVATE LIMITED	Non-Promoter	Vipin Kumar Mansukhlal Bhatt	Nil	—	16,000	16,000	0.07%
15	AXE FORTUNE CAPITAL ADVISORS LLP	Non-Promoter	Amogh Bramhe	Nil	—	12,800	12,800	0.05%
16	MINDSCOPE ADVISORS	Non-Promoter	1. Darshana	Nil	—	8,000	8,000	0.03%

	LLP	r	Malviya 2. Pallavi Daliya					
17	WINNER IMPEX PVT LTD	Non- Promote r	1. Deepa Sodhani 2. Devanshi Sodhani	Nil	—	8,000	8,000	0.03%
18	SRIRAM JEYARAMAN HUF	Non- Promote r	Sriram Jeyaraman (Karta)	Nil	—	8,000	8,000	0.03%

***Since NAV CAPITAL VCC, M7 GLOBAL FUND PCC and DOVETAIL GLOBAL FUND PCC are fund entities, disclosure of UBO is exempted under the proviso to Regulation 163(1)(f) of the SEBI ICDR Regulations.**

k) Percentage of post-preferential issue capital that may be held by the allottees and change in control:

The percentage of post-preferential issue capital that may be held by the proposed allottees is set out in the shareholding pattern table above at point (d). The Promoter & Promoter Group shareholding post the Preferential Issue is expected to be approximately 60.03% and the Public shareholding is expected to be approximately 39.97%, assuming full allotment of 1,61,82,800 equity shares.

There shall be no change in the management or control of the Company pursuant to the aforesaid Preferential Issue. The existing Promoters will continue to be the Promoters of the Company and there will be no change in the management of the Company.

l) Undertaking as to Re-computation of the share price:

Since the equity shares of the Company have been listed on BSE Limited for a period of more than 90 (Ninety) trading days prior to the Relevant Date, the price computation under Regulation 164(3) of the SEBI ICDR Regulations is not required to be re-computed, and accordingly the disclosures and undertakings required pursuant to Regulation 163(1)(g) and (h) of the SEBI ICDR Regulations are not strictly applicable. However, in compliance and out of abundant caution, the Company undertakes that it would re-compute the price of the specified securities in terms of the provisions of the SEBI ICDR Regulations, wherever required to do so.

m) Undertaking for lock-in in case of non-payment on re-computation:

The Company undertakes that if the amount payable on account of re-computation of price is not paid within the time stipulated in the SEBI ICDR Regulations, the specified securities shall continue to be locked-in till the time such amount is paid by the allottees.

n) Disclosures specified in Schedule VI of the SEBI ICDR Regulations, 2018:

Neither iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) nor its Promoters nor the Directors of the Company have been identified as a wilful defaulter or a fraudulent borrower by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India. Further, none of the Company, its Promoters or Directors have been identified as a fugitive economic offender as per the Fugitive Economic Offenders Act, 2018.

o) Current and proposed status of the allottees of equity shares post the Preferential Issue:

The current and proposed status of the proposed allottees, post the Preferential Issue, is as under:

Sr. No.	Name of the Proposed Allottee	Current Status	Proposed Status Post Preferential Issue
1	SHUBHANGI DHANRAJ GARAD	Promoter	Promoter
2	SUMEET DHANRAJ GARAD	Promoter	Promoter
3	PRATAP DADASAHEB DESHMUKH	Promoter	Promoter
4	RITU DHANRAJ GARAD	Promoter	Promoter
5	ARCHANA KAKASAHEB LONKAR	Promoter	Promoter
6	NANDKUMAR SUBHASH KADAM	Promoter	Promoter
7	DHAIRYASHEEL VASANTRAO YADAV	Promoter	Promoter
8	VENKATESH MADHAV BHAT	Non-Promoter	Promoter Group
9	PRAVIN VAMAN SURYARAO	Non-Promoter	Promoter Group
10	MADAN MANOHAR BALLAL	Non-Promoter	Promoter Group
11	DARSHANA VIKAS CHAVAN	Non-Promoter	Promoter Group
12	AADHAR KUMAR	Non-Promoter	Promoter Group
13	ISHITA RAJESH KUMAR	Non-Promoter	Promoter Group
14	UJJWALA ANIL MANE	Non-Promoter	Promoter Group
15	JYOTI MANESH WAGHIRKAR	Non-Promoter	Promoter Group
16	ARCHANA SITARAM KALE	Non-Promoter	Promoter Group
17	BABASAHEB MAHADEO BHOSALE	Non-Promoter	Promoter Group
18	SANJAY RAMCHANDRA TARLEKAR	Non-Promoter	Promoter Group
19	ANITA SUNIL NAIR	Non-Promoter	Promoter Group
20	KAMLAKAR NIVRUTTI DANDWATE	Non-Promoter	Promoter Group
21	SANJIV DATTATRAY JADHAV	Non-Promoter	Promoter Group
22	SHITAL TUSHAR PAWAR	Non-Promoter	Promoter Group
23	SANTOSH MADHAVRAV NAIK	Non-Promoter	Promoter Group
24	YOGESH INDRAJIT SOMWANSHI	Non-Promoter	Promoter Group
25	LATA SANJIV JADHAV	Non-Promoter	Promoter Group
26	SUNITA SANTOSH PATIL	Non-Promoter	Promoter Group
27	SUMAN RAVINDRA KUNJIR	Non-Promoter	Promoter Group
28	SADHANA DIGAMBAR JOSHI	Non-Promoter	Promoter Group
29	DILIP GANESH KULKARNI	Non-Promoter	Promoter Group
30	ANANT KAMLAKAR DANDAWATE	Non-Promoter	Promoter Group
31	REKHA ANIL PATIL	Non-Promoter	Promoter Group
32	DR PATIL SACHIN SHRIDHAR	Non-Promoter	Promoter Group
33	MILIND YOGESHWAR BAM	Non-Promoter	Promoter Group
34	NITIN RAMESH KULKARNI	Non-Promoter	Promoter Group
35	NIRANJAN VINAYAK DESHPANDE	Non-Promoter	Promoter Group
36	AMBADAS DATTATRAYA SHINDE	Non-Promoter	Promoter Group
37	JITENDRA PRABHAKAR NENE	Non-Promoter	Promoter Group

38	ABHIJIT MAHADEV VEER	Non-Promoter	Promoter Group
39	PRASAD DILIP NAGARE	Non-Promoter	Promoter Group
40	VINEET ARORA	Non-Promoter	Non-Promoter
41	KUNAL DEEPAK AGASHE	Non-Promoter	Non-Promoter
42	NEVILLE MANECKJI	Non-Promoter	Non-Promoter
43	DEVANATHAN GOVINDARAJAN	Non-Promoter	Non-Promoter
44	RAVI NATHAN IYER	Non-Promoter	Non-Promoter
45	DARSHAN GANGOLLI	Non-Promoter	Non-Promoter
46	MANGINA S RAO	Non-Promoter	Non-Promoter
47	AMOGH GIRISH BRAHME	Non-Promoter	Non-Promoter
48	DAMINI SANDEEP GHATE	Non-Promoter	Non-Promoter
49	MAYUR PRAKASH KARDILE	Non-Promoter	Non-Promoter
50	PARTH YASHODHAN WANAGE	Non-Promoter	Non-Promoter
51	UMA SANDEEP GHATE	Non-Promoter	Non-Promoter
52	PRATIK SHUBHKARAN SANGHI	Non-Promoter	Non-Promoter
53	MANSHA NIKHIL CHAWLA	Non-Promoter	Non-Promoter
54	SANJAY EKNATH BHOSALE	Non-Promoter	Non-Promoter
55	JYOTI KETAN VAKHARIA	Non-Promoter	Non-Promoter
56	NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND	Non-Promoter	Non-Promoter
57	M7 GLOBAL FUND PCC - CELL DEWCAP FUND	Non-Promoter	Non-Promoter
58	SAURAV RAIDANI	Non-Promoter	Non-Promoter
59	JAYARAMAN VISHWANATHAN	Non-Promoter	Non-Promoter
60	RAJESH CHANDRAKANT VAISHNAV	Non-Promoter	Non-Promoter
61	MORDE FOODS PRIVATE LIMITED	Non-Promoter	Non-Promoter
62	ERINOME ADVISORS LLP	Non-Promoter	Non-Promoter
63	GUHAPRIYA SRIDHAR	Non-Promoter	Non-Promoter
64	RAHUL HEMANTKUMAR MEHTA	Non-Promoter	Non-Promoter
65	ASMITA ROHAN PAI	Non-Promoter	Non-Promoter
66	EUDORA VENTURES LLP	Non-Promoter	Non-Promoter
67	DOVETAIL GLOBAL FUND PCC ALL SEASONS INDIA OPPORTUNITIES FUND	Non-Promoter	Non-Promoter
68	DEEPAK AGASHE HUF	Non-Promoter	Non-Promoter
69	SHANTI KALIAPPAN	Non-Promoter	Non-Promoter
70	FAT PANDA REALTY LLP	Non-Promoter	Non-Promoter
71	SHEETAL MEHTA	Non-Promoter	Non-Promoter
72	RAHUL CHANDRASINGH MEHTA	Non-Promoter	Non-Promoter
73	MARIETTA BARRETO	Non-Promoter	Non-Promoter
74	3STATE VENTURES PTE. LTD.	Non-Promoter	Non-Promoter
75	NIKHIL TYAGI	Non-Promoter	Non-Promoter
76	AMIT J DHOLAKIA HUF	Non-Promoter	Non-Promoter

77	VISHAL ULHAS DHUMAL	Non-Promoter	Non-Promoter
78	DEEPSHIKHA ARORA	Non-Promoter	Non-Promoter
79	SAJID UMEDALI DHROLIA	Non-Promoter	Non-Promoter
80	KULBHUSHAN PARASHAR	Non-Promoter	Non-Promoter
81	ANURADHA HARSHAL MORDE	Non-Promoter	Non-Promoter
82	REX EQUITY	Non-Promoter	Non-Promoter
83	KALAWATI KISHOR THAKKAR	Non-Promoter	Non-Promoter
84	SUNIL POPATLAL NAHAR	Non-Promoter	Non-Promoter
85	RASHMI YASHDEEP JOSHI	Non-Promoter	Non-Promoter
86	BHAVNA GOTHI	Non-Promoter	Non-Promoter
87	MUKKTA NEVILLE MANECKJI	Non-Promoter	Non-Promoter
88	VIKAS ARORA	Non-Promoter	Non-Promoter
89	ABHAY PRABHAKAR HAVALDAR	Non-Promoter	Non-Promoter
90	MALIK AMIRBHAI CHARANIYA	Non-Promoter	Non-Promoter
91	ASHOK BHAWANDAS AWTANI	Non-Promoter	Non-Promoter
92	DIVESH WADHAWAN	Non-Promoter	Non-Promoter
93	NETRADEEP EYE HOSPITAL PRIVATE LTD	Non-Promoter	Non-Promoter
94	AMISHA NIRAJ VORA	Non-Promoter	Non-Promoter
95	NERGIS GAURAV PARIKH	Non-Promoter	Non-Promoter
96	SAROD REALITY PRIVATE LIMITED	Non-Promoter	Non-Promoter
97	PRATIM SENGUPTA	Non-Promoter	Non-Promoter
98	BIJAL KUNAL THAKKAR	Non-Promoter	Non-Promoter
99	SIDDARTH MURALI KONTHATH	Non-Promoter	Non-Promoter
100	JASPRIT J BUMRAH	Non-Promoter	Non-Promoter
101	SHILPA ASHWIN RANGDAL	Non-Promoter	Non-Promoter
102	VINIT BIPIN SHAH	Non-Promoter	Non-Promoter
103	ROHIT SHARMA	Non-Promoter	Non-Promoter
104	DILIP KESHRIKAL SANKLECHA	Non-Promoter	Non-Promoter
105	CHANDRASHEKHAR RAJARAM KULKARNI	Non-Promoter	Non-Promoter
106	AAMIR KHAN	Non-Promoter	Non-Promoter
107	KANNAN KRISHNAMURTI NAIDU	Non-Promoter	Non-Promoter
108	CHANNA KESHAVA HOSAGAVI	Non-Promoter	Non-Promoter
109	RANBIR RISHI KAPOOR	Non-Promoter	Non-Promoter
110	SHILPA NARENDRA HIRANI	Non-Promoter	Non-Promoter
111	BIMAL PAREKH	Non-Promoter	Non-Promoter
112	KINGSMAN WEALTH MANAGEMENT PRIVATE LIMITED	Non-Promoter	Non-Promoter
113	SUNIL GOVINDLAL BHANDARI	Non-Promoter	Non-Promoter
114	JASKARAN SINGH	Non-Promoter	Non-Promoter
115	KISHORE KANJI THAKKAR	Non-Promoter	Non-Promoter
116	ARUN MAFATLAL PRAJAPATI	Non-Promoter	Non-Promoter

117	BIBHAS DASGUPTA	Non-Promoter	Non-Promoter
118	MANOJ BAVANJIBHAI BAVARIA	Non-Promoter	Non-Promoter
119	AJAY AGNIHOTRI	Non-Promoter	Non-Promoter
120	JYOTSNA MEHTA	Non-Promoter	Non-Promoter
121	MANOJ SHIV LAUNGANI	Non-Promoter	Non-Promoter
122	SHALINI ASHOK CHAWLA	Non-Promoter	Non-Promoter
123	ANKITA CHOPRA	Non-Promoter	Non-Promoter
124	AXE FORTUNE CAPITAL ADVISORS LLP	Non-Promoter	Non-Promoter
125	ABHISHEK NARBARIA	Non-Promoter	Non-Promoter
126	UMESH KUMAR SAHAY	Non-Promoter	Non-Promoter
127	RESHMA MANOJ MOHNANI	Non-Promoter	Non-Promoter
128	RASHMI SARAFF	Non-Promoter	Non-Promoter
129	DINESHKUMAR S RAWLANI	Non-Promoter	Non-Promoter
130	SETHIYA SACHIN KANTILAL	Non-Promoter	Non-Promoter
131	ESHA SAVLANI	Non-Promoter	Non-Promoter
132	S NAGESHWARAN	Non-Promoter	Non-Promoter
133	MINDSCOPE ADVISORS LLP	Non-Promoter	Non-Promoter
134	MUKESH MANOHAR YEOLE	Non-Promoter	Non-Promoter
135	SRINIVASAN ROHINI	Non-Promoter	Non-Promoter
136	ILESH H SANGHANI	Non-Promoter	Non-Promoter
137	ARWA ALVARES	Non-Promoter	Non-Promoter
138	LADDHA NIKHIL RAMESHKUMAR	Non-Promoter	Non-Promoter
139	BHAKTI BIMAL PAREKH	Non-Promoter	Non-Promoter
140	PRANAV NAVINCHANDRA DOCTOR	Non-Promoter	Non-Promoter
141	KALLAM SRINIVAS REDDY	Non-Promoter	Non-Promoter
142	NEELA GOPALAKRISHNAN	Non-Promoter	Non-Promoter
143	WINNER IMPEX PVT LTD	Non-Promoter	Non-Promoter
144	PRAGNESH A SHAH	Non-Promoter	Non-Promoter
145	PARUL KARTIK VAKHARIA	Non-Promoter	Non-Promoter
146	KRISHNAKUMAR RATANKUMAR MOHTA	Non-Promoter	Non-Promoter
147	NIMISHA GORAKSHAKAR	Non-Promoter	Non-Promoter
148	SUNIL SURESHCHANDRA PHADE	Non-Promoter	Non-Promoter
149	KAPIL DHIRAJ THAKKAR	Non-Promoter	Non-Promoter
150	TAPAS SAHA	Non-Promoter	Non-Promoter
151	MAULALI CHANDSAHEB JAMADAR	Non-Promoter	Non-Promoter
152	AAMER DE	Non-Promoter	Non-Promoter
153	DHANANJAY PUNDLIK WAKUDKAR	Non-Promoter	Non-Promoter
154	SRIRAM JEYARAMAN HUF	Non-Promoter	Non-Promoter
155	VINAY KUMAR	Non-Promoter	Non-Promoter
156	GIRISH PUKHRAJ PORWAL	Non-Promoter	Non-Promoter
157	MUKESH BHAGWANLAL SHINGI	Non-Promoter	Non-Promoter

158	MANISH SHANKARLAL RATHI	Non-Promoter	Non-Promoter
159	SAHAJ BIMAL PAREKH	Non-Promoter	Non-Promoter
160	SAMPATH KUMAR AMUDHA	Non-Promoter	Non-Promoter
161	PONNAKATTI RAJAN UDAY KUMAR	Non-Promoter	Non-Promoter
162	PONNAGATIKUPPUSWAMY JAYARAMAN	Non-Promoter	Non-Promoter
163	PONNAI CHOKALINGAM MANI	Non-Promoter	Non-Promoter
164	JAYANT DIGAMBAR PATKAR	Non-Promoter	Non-Promoter
165	NEHA ALTAMASH AHMED	Non-Promoter	Non-Promoter
166	PRANAY PRITHVIRAJ CHOUHAN	Non-Promoter	Non-Promoter
167	NRIP NIHALANI	Non-Promoter	Non-Promoter
168	VERSHA SHARMA	Non-Promoter	Non-Promoter
169	ASHISH SURJEET MAKHIJANI	Non-Promoter	Non-Promoter
170	MURALI NAGARAJAN	Non-Promoter	Non-Promoter
171	KARAN RAJEEV GOYAL	Non-Promoter	Non-Promoter
172	ROSHAAN MADHUKAR NARKEDAYY	Non-Promoter	Non-Promoter
173	ARCHANA AMAR MULE	Non-Promoter	Non-Promoter
174	VINAYAK CHANDRAKANT SANAS	Non-Promoter	Non-Promoter
175	RAM PRASAD LADI	Non-Promoter	Non-Promoter
176	SHIFA MAKSUD MULANI	Non-Promoter	Non-Promoter
177	SIDDARTH JAIN	Non-Promoter	Non-Promoter
178	SIDDHANT MANGESH DOSHI	Non-Promoter	Non-Promoter
179	ADITYA VIVEK PATKAR	Non-Promoter	Non-Promoter
180	SAMARTH MEHTA	Non-Promoter	Non-Promoter
181	RAJA JEPPEAN	Non-Promoter	Non-Promoter
182	KATTELA RAMESH	Non-Promoter	Non-Promoter
183	SAHIL MEHTA	Non-Promoter	Non-Promoter
184	SHRIKANT LAXMAN KHAJGIWALE	Non-Promoter	Non-Promoter
185	PRASANNA SHRIKANT KHAJGIWALE	Non-Promoter	Non-Promoter
186	ATUL KANTILAL SHAH	Non-Promoter	Non-Promoter
187	KETAN PRAVEEN RANGA	Non-Promoter	Non-Promoter
188	RAKESH PRAKASH SHARMA	Non-Promoter	Non-Promoter
189	THURUPHATI SHEKAR	Non-Promoter	Non-Promoter
190	KARTHIKEYAN BALAKRISHNA	Non-Promoter	Non-Promoter
191	MASILAMANI NARAYANASWAMY PONNANGATI	Non-Promoter	Non-Promoter
192	MOHAN RAO AVANURI	Non-Promoter	Non-Promoter
193	GIRIPRASAD NARAYANAN	Non-Promoter	Non-Promoter
194	KALIYUR SELVAMANI RAMANUJAM	Non-Promoter	Non-Promoter
195	ANSHUL ABHISHEK	Non-Promoter	Non-Promoter
196	LOGANATHAN MEENAKSHISUNDARAM	Non-Promoter	Non-Promoter

Lock-in Period:

The equity shares allotted pursuant to the Preferential Issue shall be locked-in for such period as may be specified under Chapter V of the SEBI ICDR Regulations:

- a) Direct Promoters (7 persons – 68,80,500 shares): Lock-in for 18 (Eighteen) months from the date of trading approval granted by BSE Limited, in terms of Regulation 167(1) of the SEBI ICDR Regulations.
- b) Promoter Group (32 persons – 17,32,500 shares): In terms of Regulation 167(1) of the SEBI ICDR Regulations, equity shares allotted to Promoters and Promoter Group on a preferential basis shall be locked-in for 18 (Eighteen) months, subject to the condition that the total number of equity shares locked-in pursuant to Regulation 167(1) shall not exceed 20% of the total post-issue paid-up equity share capital of the Company. The post-issue paid-up equity share capital of the Company is 2,45,91,772 shares, and 20% thereof amounts to 49,18,354 shares. Since the Direct Promoters alone are being allotted 68,80,500 shares under this Preferential Issue – which already exceeds the said 20% cap of 49,18,354 shares – no further lock-in under Regulation 167(1) can be applied to the Promoter Group allottees. Accordingly, the equity shares allotted to the 32 Promoter Group allottees (17,32,500 shares) shall be locked-in for 6 (Six) months from the date of trading approval, in terms of Regulation 167(2) of the SEBI ICDR Regulations.
- c) Non-Promoter / Public (157 persons – 75,69,800 shares): Lock-in for 6 (Six) months from the date of trading approval, in terms of Regulation 167(2) of the SEBI ICDR Regulations.

The entire pre-preferential allotment shareholding of all proposed allottees (if any) shall be locked-in from the Relevant Date up to a period of 90 (Ninety) trading days from the date of trading approval, as specified under Regulation 167(6) of the SEBI ICDR Regulations.

Practicing Company Secretary's Certificate [Regulation 163(2)]:

The certificate from Ms. Seema Chaudhary, Practicing Company Secretary (Membership No.: A45413; COP No.: 27689), having office at 30, Guru Ram Das Nagar, Laxmi Nagar, New Delhi – 110092, Email: csseemachaudhary.cfl@gmail.com, certifying that the Preferential Issue is being made in accordance with the requirements of Chapter V of the SEBI ICDR Regulations shall be available for inspection by the Members and the same may be accessed on the website of the Company at www.covidhtechnologies.com.

Number of persons to whom allotment on preferential basis has already been made during the year:

During the current financial year 2026-27, the Company has not made any allotment of securities on a preferential basis.

Other Disclosures:

- a) The Company is eligible to make the Preferential Issue under Chapter V of the SEBI ICDR Regulations and is in compliance with the conditions for continuous listing of equity shares as specified in the Listing Agreement with BSE Limited.
- b) Neither the Company nor any of its Directors or Promoters are categorized as wilful defaulter(s) by any bank or financial institution or consortium thereof, in accordance with the guidelines on wilful defaulter(s) issued by the Reserve Bank of India. Further, neither the Company nor any of its Directors or Promoters is a fraudulent borrower or a fugitive economic offender as defined under the SEBI ICDR Regulations.
- c) The proposed preferential issue is not being made to any body corporate incorporated in, or a national of, a country that shares a land border with India.
- d) The Company does not have any outstanding dues to SEBI, BSE Limited or the depositories.

- e) The Company has obtained the Permanent Account Numbers (PAN) of all 196 proposed allottees before making the application seeking In-Principle Approval from BSE Limited.
- f) The Company filed / shall file the application seeking In-Principle Approval from BSE Limited on the same day as the date of dispatch of this Postal Ballot Notice to the shareholders, i.e., Tuesday, April 21, 2026, in accordance with Regulation 160(6) of the SEBI ICDR Regulations.
- g) The proposed preferential issue is in accordance with the provisions of the Memorandum of Association and Articles of Association of the Company (including the new set of MOA and AOA proposed to be adopted pursuant to Item Nos. 2 and 3 of this Postal Ballot Notice) and is not ultra-vires thereto.
- h) All proposed allottees have confirmed that they have not sold or transferred any equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) during the period of 90 (Ninety) trading days preceding the Relevant Date.
- i) The equity shares shall be issued and allotted in dematerialized form only, credited to the demat accounts of the respective allottees.
- j) Since this preferential issue is for consideration other than cash (share swap), no monetary proceeds shall be received by the Company. The consideration is discharged entirely by surrender of Sale Shares of iSERA Biological Limited to the Company pursuant to the Share Swap Agreement.
- k) In case any proposed allottee fails to transfer the Sale Shares of iSERA Biological Limited to the Company, the Company shall not allot any equity shares to such allottee.
- l) The proposed Preferential Issue is not expected to result in a change in control of the Company.
- m) This preferential issue is being made strictly in accordance with applicable law and shall comply at all times with the minimum public shareholding requirements prescribed under the Securities Contracts (Regulation) Rules, 1957, as amended, and Regulation 38 of the SEBI Listing Regulations.

Accordingly, the approval of the Members of the Company is hereby sought by way of a Special Resolution for authorising the Board of Directors of the Company to create, offer, issue and allot equity shares as specifically described in the resolution set out at Item No. 7 of this Notice.

The Board of Directors of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) believes that the proposed preferential issue is in the best interests of the Company and its Members and recommends the Special Resolution set out at Item No. 7 for approval by the Members.

The Promoters / Directors of the Company who are shareholders of iSERA Biological Limited and therefore proposed allottees under this Preferential Issue, namely Shubhangi Dhanraj Garad, Sumeet Dhanraj Garad, Pratap Dadasaheb Deshmukh, Ritu Dhanraj Garad, Archana Kakasaheb Lonkar, Nandkumar Subhash Kadam, Dhairyasheel Vasantrao Yadav and Jitendra Prabhakar Nene, may be deemed to be interested in this resolution. None of the other Directors or Key Managerial Personnel of the Company or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 7 of this Notice, except to the extent of their respective shareholding in the Company, if any.

Date: April 21, 2026

Place: Pune

By order of Board of Directors
For iSERA Lifesciences Limited
(Formerly known as Covidh Technologies Limited)

SD/-

Deepakshi
Company Secretary and Compliance Officer
Membership No.: A76335